

PROxAb Shuttle in-vivo

2024-06-03 Created

2024-06-14 Add metabolites

2024-08-09 Add ADC with 2 free arms


2024-08-09 MoA Protacs (ubiquitination in 1 step)

!! Be aware app parameters labeled with Ab
correspond to those in this presentation labeled with ADC !!

E.g.


presentation $CL_{ADC} = CL_{Ab}$ app

Mathematical description of mechanisms in-vivo




Mathematical description of mechanisms in-vivo

Metabolites




(Un-)Binding of Protacs and Metabolites in central compartment and tumor extracellular space



Same reactions apply to tumor extracellular space ex. But in peripheral space C2 we have only drug (un-)binding

(Un-)Binding of Protacs and Metabolites in central compartment and tumor extracellular space




Same reactions apply to tumor extracellular space ex. But in peripheral space C2 we have only **drug (un-)binding**

$$\longleftrightarrow K_{on}^{Ab,Meta} + K_{off}^{Ab,Meta}$$


$$\longleftrightarrow K_{on}^{Ab,Drug} + K_{off}^{Ab,Drug}$$

Mathematical description of mechanisms in-vivo



Mathematical description of mechanisms in-vivo

Protac MoA



Average drug-to-antibody ratio for covalent bound ADC

$$\frac{d(\overline{DAR})}{dt} = \underbrace{-K_{dec}^{ADC} \times \overline{DAR}}_{\text{Due to non-specific deconjugation of ADC}}$$

Mean DAR in plasma (only Protacs)

$$\begin{aligned} meanDAR = & \frac{(Ab_f^{C1} \times 0 + \sum_{i=1}^{max} Ab_{bi}^{C1} \times i + \sum_{j=1}^{max-1} Ab_{b1,mj}^{C1} \times 1 + \sum_{j=1}^{max-2} Ab_{b2,mj}^{C1} \times 2 + Ab_{b3,m1}^{C1} \times 3) \times \frac{BW}{SF}}{\left(\sum_{i=0}^{max} Ab_{bi}^{C1} + \sum_{j=1}^{max} Ab_{mj}^{C1} + \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj}^{C1} \right) \times \frac{BW}{SF}} \\ & + \left(\frac{\sum_{i=1}^2 ADC_{bi}^{C1} \times i + ADC_{b1,m1}^{C1}}{\sum_{i=0}^2 ADC_{bi}^{C1} + \sum_{j=1}^2 ADC_{mj}^{C1} + ADC_{b1,m1}^{C1}} + DAR \right) \times \frac{\sum_{i=0}^2 ADC_{bi}^{C1} + \sum_{j=1}^2 ADC_{mj}^{C1} + ADC_{b1,m1}^{C1}}{\sum_{i=0}^2 ADC_{bi}^{C1} + \sum_{j=1}^2 ADC_{mj}^{C1} + ADC_{b1,m1}^{C1} + \left(\sum_{i=0}^{max} Ab_{bi}^{C1} + \sum_{j=1}^{max} Ab_{mj}^{C1} + \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj}^{C1} \right)} \end{aligned}$$

Amount of free ADC (nmol/kg) (bound to 0 Protacs) in central compartment

$$\frac{d(ADC_f^{C1})}{dt} = \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times ADC_f^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times ADC_f^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times ADC_f^{C2}}_{\text{From peripheral space}}$$

$$- \underbrace{\left(\frac{ADC_f^{C1}}{V_{ADC}^{C1}} - \frac{ADC_f^{ex}}{\varepsilon^{ADC}} \right) \times \frac{V^{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{To tumor extracellular space}}$$

$$\underbrace{-K_{on}^{Ab,Drug} \times 2 \times ADC_f^{C1} \times Drug_f^{C1}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times ADC_{b1}^{C1}}_{\text{From unbinding of drug}} - \underbrace{K_{on}^{Ab,Meta} \times 2 \times ADC_f^{C1} \times Meta1_f^{C1}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times ADC_{m1}^{C1}}_{\text{From unbinding of metabolite}}$$

Units: $\frac{nmol}{kg \times h} = \frac{\frac{l}{kg}}{\frac{h}{l/kg}} \times \frac{nmol}{kg} - \frac{\frac{l}{kg}}{\frac{h}{l/kg}} \times nmol/kg + \frac{\frac{l}{kg}}{\frac{h}{l/kg}} \times nmol/kg - \left(\frac{nmol/kg}{l/kg} - \frac{nmol/l}{1} \right) \times \frac{l}{kg} \times \left(\frac{\frac{um}{h} \times um}{um^2} + \frac{cm^2/h}{cm^2} \right)$

$$- \frac{l}{h} \times \left(\frac{1}{l/kg \times kg} \right) \times \frac{nmol}{kg} - \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol}{kg} \times (1 - 1 - 1) \times 1 \times \frac{nmol}{kg \times \frac{l}{kg}} + \frac{1}{h} \times 1 \times 1 \times \frac{nmol}{kg} - \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol}{kg} \times \frac{nmol}{kg \times \frac{l}{kg}} + \frac{1}{h} \times \frac{nmol}{kg}$$

Amount (nmol/kg) of ADC bound to 1 Protac in central compartment/plasma

$$\frac{d(ADC_{b1}^{C1})}{dt} = \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times ADC_{b1}^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times ADC_{b1}^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times ADC_{b1}^{C2}}_{\text{From peripheral space}}$$

$$\underbrace{-\left(\frac{ADC_{b1}^{C1}}{V_{ADC}^{C1}} - \frac{ADC_{b1}^{ex}}{\varepsilon^{ADC}}\right) \times \frac{V^{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2}\right)}_{\text{To tumor extracellular space}} - \underbrace{K_{on}^{Ab,Drug} \times ADC_{b1}^{C1} \times Drug_f^{C1}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times ADC_{b1}^{C1}}_{\text{From unbinding of drug}}$$

$$\underbrace{+K_{on}^{Ab,Drug} \times 2 \times ADC_f^{C1} \times Drug_f^{C1}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times ADC_{b1}^{C1}}_{\text{To unbinding of drug}} - \underbrace{K_{on}^{Ab,Meta} \times ADC_{b1}^{C1} \times Meta1_f^{C1}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times ADC_{b1,m1}^{C1}}_{\text{From unbinding of metabolite}}$$

Amount (nmol/kg) of ADC bound to 2 Protacs in central compartment/plasma

$$\begin{aligned}
 \frac{d(ADC_{b2}^{C1})}{dt} = & \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times ADC_{b2}^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times ADC_{b2}^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times ADC_{b2}^{C2}}_{\text{From peripheral space}} \\
 & - \underbrace{\left(\frac{ADC_{b2}^{C1}}{V_{ADC}^{C1}} - \frac{ADC_{b2}^{ex}}{\varepsilon^{ADC}} \right) \times \frac{V^{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{To tumor extracellular space}} \\
 & + \underbrace{K_{on}^{Ab,Drug} \times ADC_{b1}^{C1} \times Drug_f^{C1}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times ADC_{b2}^{C1}}_{\text{To unbinding of drug}}
 \end{aligned}$$

Amount (nmol/kg) of ADC bound to 1 Metabolite1 in central compartment/plasma

$$\frac{d(ADC_{m1}^{C1})}{dt} = \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times ADC_{m1}^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times ADC_{m1}^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times ADC_{m1}^{C2}}_{\text{From peripheral space}}$$

$$\underbrace{-\left(\frac{ADC_{m1}^{C1}}{V_{ADC}^{C1}} - \frac{ADC_{m1}^{ex}}{\varepsilon^{ADC}}\right) \times \frac{V^{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2}\right)}_{\text{To tumor extracellular space}} - \underbrace{K_{on}^{Ab,Drug} \times ADC_{m1}^{C1} \times Drug_f^{C1}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times ADC_{b1,m1}^{C1}}_{\text{From unbinding of drug}}$$

$$\underbrace{+K_{on}^{Ab,Meta} \times 2 \times ADC_f^{C1} \times Meta1_f^{C1}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times ADC_{m1}^{C1}}_{\text{To unbinding of metabolite}} - \underbrace{K_{on}^{Ab,Meta} \times ADC_{m1}^{C1} \times Meta1_f^{C1}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times ADC_{m2}^{C1}}_{\text{From unbinding of metabolite}}$$

Amount (nmol/kg) of ADC bound to 2 Metabolites1 in central compartment/plasma

$$\begin{aligned}
 \frac{d(ADC_{m2}^{C1})}{dt} = & \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times ADC_{m2}^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times ADC_{m2}^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times ADC_{m2}^{C2}}_{\text{From peripheral space}} \\
 & - \underbrace{\left(\frac{ADC_{m2}^{C1}}{V_{ADC}^{C1}} - \frac{ADC_{m2}^{ex}}{\varepsilon^{ADC}} \right) \times \frac{V^{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{To tumor extracellular space}} \\
 & + \underbrace{K_{on}^{Ab,Meta} \times ADC_{m1}^{C1} \times Meta1_f^{C1}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times ADC_{m2}^{C1}}_{\text{To unbinding of metabolite}}
 \end{aligned}$$

Amount (nmol/kg) of ADC bound to 1 Protac and 1 Metabolite1 in central compartment/plasma

$$\frac{d(ADC_{b1,m1}^{C1})}{dt} = \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times ADC_{b1,m1}^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times ADC_{b1,m1}^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times ADC_{b1,m1}^{C2}}_{\text{From peripheral space}}$$

$$- \underbrace{\left(\frac{ADC_{b1,m1}^{C1}}{V_{ADC}^{C1}} - \frac{ADC_{b1,m1}^{ex}}{\varepsilon^{ADC}} \right) \times \frac{V^{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{To tumor extracellular space}}$$

To tumor extracellular space

$$\underbrace{+K_{on}^{Ab,Drug} \times ADC_{m1}^{C1} \times Drug_f^{C1}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times ADC_{b1,m1}^{C1}}_{\text{To unbinding of drug}}$$

From binding to drug

To unbinding of drug

$$\underbrace{+K_{on}^{Ab,Meta} \times ADC_{b1}^{C1} \times Meta1_f^{C1}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times ADC_{b1,m1}^{C1}}_{\text{To unbinding of metabolite}}$$

From binding to metabolite

To unbinding of metabolite

Amount (nmol/kg) of free Antibody (bound to 0 Protacs) in central compartment/plasma

$$\frac{d(Ab_f^{C1})}{dt} = \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times Ab_f^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_f^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_f^{C2}}_{\text{From peripheral space}}$$

$$\underbrace{-\left(\frac{Ab_f^{C1}}{V_{ADC}^{C1}} - \frac{Ab_f^{ex}}{\varepsilon_{ADC}}\right) \times \frac{V_{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2}\right)}_{\text{To tumor extracellular space}} - \underbrace{K_{on}^{Ab,Drug} \times max \times Ab_f^{C1} \times Drug_f^{C1}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times Ab_{b1}^{C1}}_{\text{From unbinding of drug}}$$

$$\underbrace{-K_{on}^{Ab,Meta} \times max \times Ab_f^{C1} \times Meta1_f^{C1}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times Ab_{m1}^{C1}}_{\text{From unbinding of metabolite}}$$

Units: $\frac{nmol}{kg \times h} = \frac{\frac{l}{h/kg}}{\frac{l}{kg}} \times \frac{nmol}{kg} - \frac{\frac{l}{h/kg}}{\frac{l}{kg}} \times nmol/kg + \frac{\frac{l}{h/kg}}{\frac{l}{kg}} \times nmol/kg - \left(\frac{nmol/kg}{l/kg} - \frac{nmol/l}{1}\right) \times \frac{l}{kg} \times \left(\frac{\frac{um}{h} \times um}{um^2} + \frac{cm^2/h}{cm^2}\right)$

$$- \frac{l}{h} \times \left(\frac{1}{l/kg \times kg}\right) \times \frac{nmol}{kg} - \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol}{kg} \times (1 - 1 - 1) \times 1 \times \frac{nmol}{kg \times \frac{l}{kg}} + \frac{1}{h} \times 1 \times 1 \times \frac{nmol}{kg} - \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol}{kg} \times \frac{nmol}{kg \times \frac{l}{kg}} + \frac{1}{h} \times \frac{nmol}{kg}$$

Amount (nmol/kg) of Antibody bound to i Protacs in central compartment/plasma, i = 1,2,3

$$\begin{aligned}
 \frac{d(Ab_{bi}^{C1})}{dt} = & \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times Ab_{bi}^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_{bi}^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_{bi}^{C2}}_{\text{From peripheral space}} \\
 & - \underbrace{\left(\frac{Ab_{bi}^{C1}}{V_{ADC}^{C1}} - \frac{Ab_{bi}^{ex}}{\varepsilon_{ADC}} \right) \times \frac{V_{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{To tumor extracellular space}} \\
 & - \underbrace{K_{on}^{Ab,Drug} \times (max - i) \times Ab_{bi}^{C1} \times Drug_f^{C1}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi+1}^{C1}}_{\text{From unbinding of drug}} \\
 & + \underbrace{K_{on}^{Ab,Drug} \times (max - i + 1) \times Ab_{bi-1}^{C1} \times Drug_f^{C1}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi}^{C1}}_{\text{To unbinding of drug}} \\
 & - \underbrace{K_{on}^{Ab,Meta} \times (max - i) \times Ab_{bi}^{C1} \times Meta1_f^{C1}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times Ab_{bi+1}^{C1}}_{\text{From unbinding of metabolite}}
 \end{aligned}$$

Units: $\frac{nmol}{kg \times h} = \frac{\frac{l}{kg}}{\frac{h}{kg}} \times \frac{nmol}{kg} - \frac{\frac{l}{kg}}{\frac{l}{kg}} \times nmol/kg + \frac{\frac{l}{kg}}{\frac{l}{kg}} \times nmol/kg - \left(\frac{nmol/kg}{l/kg} - \frac{nmol/l}{1} \right) \times \frac{l}{kg} \times \left(\frac{\frac{um}{h} \times um}{um^2} + \frac{cm^2/h}{cm^2} \right)$

$$- \frac{l}{h} \times \left(\frac{1}{l/kg \times kg} \right) \times \frac{nmol}{kg} - \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol}{kg} \times (1 - 1 - 1) \times 1 \times \frac{nmol}{kg \times \frac{l}{kg}} + \frac{1}{h} \times 1 \times 1 \times \frac{nmol}{kg} - \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol}{kg} \times \frac{nmol}{kg \times \frac{l}{kg}} + \frac{1}{h} \times \frac{nmol}{kg}$$

Amount (nmol/kg) of Antibody bound to 4 Protacs in central compartment/plasma

$$\frac{d(Ab_{b4}^{C1})}{dt} = \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times Ab_{b4}^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_{b4}^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_{b4}^{C2}}_{\text{From peripheral space}}$$

$$\underbrace{-\left(\frac{Ab_{b4}^{C1}}{V_{ADC}^{C1}} - \frac{Ab_{b4}^{ex}}{\varepsilon^{ADC}}\right) \times \frac{V^{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2}\right)}_{\text{To tumor extracellular space}}$$

$$\underbrace{+K_{on}^{Ab,Drug} \times Ab_{b3}^{C1} \times Drug_f^{C1}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times Ab_{b4}^{C1}}_{\text{To unbinding of drug}}$$

Units: $\frac{nmol}{kg \times h} = \frac{\frac{l}{kg}}{\frac{h}{kg}} \times \frac{nmol}{kg} - \frac{\frac{l}{kg}}{\frac{l}{kg}} \times nmol/kg + \frac{\frac{l}{kg}}{\frac{l}{kg}} \times nmol/kg - \left(\frac{nmol/kg}{l/kg} - \frac{nmol/l}{1}\right) \times \frac{l}{kg} \times \left(\frac{\frac{um}{h} \times um}{um^2} + \frac{cm^2/h}{cm^2}\right)$
 $- \frac{l}{h} \times \left(\frac{1}{l/kg \times kg}\right) \times \frac{nmol}{kg} - \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol}{kg} \times (1 - 1 - 1) \times 1 \times \frac{nmol}{kg \times \frac{l}{kg}} + \frac{1}{h} \times 1 \times 1 \times \frac{nmol}{kg} - \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol}{kg} \times \frac{nmol}{kg \times \frac{l}{kg}} + \frac{1}{h} \times \frac{nmol}{kg}$

Amount (nmol/kg) of Antibody bound to j Metabolites1 in central compartment/plasma, j = 1,2,3

$$\frac{d(Ab_{mj}^{C1})}{dt} = \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times Ab_{mj}^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_{mj}^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_{mj}^{C2}}_{\text{From peripheral space}}$$

$$\underbrace{-\left(\frac{Ab_{mj}^{C1}}{V_{ADC}^{C1}} - \frac{Ab_{mj}^{ex}}{\varepsilon_{ADC}}\right) \times \frac{V_{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2}\right)}_{\text{To tumor extracellular space}} - \underbrace{K_{on}^{Ab,Drug} \times (max - j) \times Ab_{mj}^{C1} \times Drug_f^{C1}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times Ab_{b1,mj}^{C1}}_{\text{From unbinding of drug}}$$

$$\underbrace{+K_{on}^{Ab,Meta} \times (max - j + 1) \times Ab_{mj-1}^{C1} \times Meta1_f^{C1}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times Ab_{mj}^{C1}}_{\text{To unbinding of metabolite}} - \underbrace{K_{on}^{Ab,Meta} \times (max - j) \times Ab_{mj}^{C1} \times Meta1_f^{C1}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times Ab_{mj}^{C1}}_{\text{From unbinding of metabolite}}$$

Units: $\frac{nmol}{kg \times h} = \frac{\frac{l}{kg}}{\frac{h}{l/kg}} \times \frac{nmol}{kg} - \frac{\frac{l}{kg}}{\frac{h}{l/kg}} \times nmol/kg + \frac{\frac{l}{kg}}{\frac{h}{l/kg}} \times nmol/kg - \left(\frac{nmol/kg}{l/kg} - \frac{nmol/l}{1}\right) \times \frac{l}{kg} \times \left(\frac{\frac{um}{h} \times um}{um^2} + \frac{cm^2/h}{cm^2}\right)$

$$- \frac{l}{h} \times \left(\frac{1}{l/kg \times kg}\right) \times \frac{nmol}{kg} - \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol}{kg} \times (1 - 1 - 1) \times 1 \times \frac{nmol}{kg \times \frac{l}{kg}} + \frac{1}{h} \times 1 \times 1 \times \frac{nmol}{kg} - \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol}{kg} \times \frac{nmol}{kg \times \frac{l}{kg}} + \frac{1}{h} \times \frac{nmol}{kg}$$

Amount (nmol/kg) of Antibody bound to 4 Metabolites¹ in central compartment/plasma

$$\frac{d(Ab_{m4}^{C1})}{dt} = \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times Ab_{m4}^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_{m4}^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_{m4}^{C2}}_{\text{From peripheral space}}$$

$$\underbrace{-\left(\frac{Ab_{m4}^{C1}}{V_{ADC}^{C1}} - \frac{Ab_{m4}^{ex}}{\varepsilon^{ADC}}\right) \times \frac{V^{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2}\right)}_{\text{To tumor extracellular space}}$$

$$\underbrace{+K_{on}^{Ab,Meta} \times Ab_{m3}^{C1} \times Meta1_f^{C1}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times Ab_{m4}^{C1}}_{\text{To unbinding of metabolite}}$$

Units: $\frac{nmol}{kg \times h} = \frac{\frac{l}{kg}}{\frac{h}{kg}} \times \frac{nmol}{kg} - \frac{\frac{l}{kg}}{\frac{l}{kg}} \times nmol/kg + \frac{\frac{l}{kg}}{\frac{l}{kg}} \times nmol/kg - \left(\frac{nmol/kg}{l/kg} - \frac{nmol/l}{1}\right) \times \frac{l}{kg} \times \left(\frac{\frac{um}{h} \times um}{um^2} + \frac{cm^2/h}{cm^2}\right)$
 $- \frac{l}{h} \times \left(\frac{1}{l/kg \times kg}\right) \times \frac{nmol}{kg} - \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol}{kg} \times (1 - 1 - 1) \times 1 \times \frac{nmol}{kg \times \frac{l}{kg}} + \frac{1}{h} \times 1 \times 1 \times \frac{nmol}{kg} - \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol}{kg} \times \frac{nmol}{kg \times \frac{l}{kg}} + \frac{1}{h} \times \frac{nmol}{kg}$

Amount (nmol/kg) of Antibody bound to i Protac and j Metabolites1 in central compartment/plasma, i = 1,2 and j = 1,2 with i + j < max

$$\frac{d(Ab_{bi,mj}^{C1})}{dt} = \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times Ab_{bi,mj}^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_{bi,mj}^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_{bi,mj}^{C2}}_{\text{From peripheral space}}$$

$$\underbrace{-\left(\frac{Ab_{bi,mj}^{C1}}{V_{ADC}^{C1}} - \frac{Ab_{bi,mj}^{ex}}{\varepsilon_{ADC}}\right) \times \frac{V^{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2}\right)}_{\text{To tumor extracellular space}} - \underbrace{K_{on}^{Ab,Drug} \times (max - i - j) \times Ab_{bi,mj}^{C1} \times Drug_f^{C1}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi,mj}^{C1}}_{\text{From unbinding of drug}}$$

$$\underbrace{+K_{on}^{Ab,Drug} \times (max - i + 1 - j) \times Ab_{bi-1,mj}^{C1} \times Drug_f^{C1}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi,mj}^{C1}}_{\text{To unbinding of drug}} - \underbrace{K_{on}^{Ab,Meta} \times (max - i - j) \times Ab_{bi,mj}^{C1} \times Meta1_f^{C1}}_{\text{To binding to metabolite}}$$

$$\underbrace{+K_{off}^{Ab,Meta} \times Ab_{bi,mj+1}^{C1}}_{\text{From unbinding of metabolite}} + \underbrace{K_{on}^{Ab,Meta} \times (max - i - j + 1) \times Ab_{bi,mj-1}^{C1} \times Meta1_f^{C1}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times Ab_{bi,mj}^{C1}}_{\text{To unbinding of metabolite}}$$

Amount (nmol/kg) of Antibody bound to i Protac and j Metabolites1 in central compartment/plasma, i = 1,2,3 and j = 1,2,3 with i + j = max

$$\frac{d(Ab_{bi,mj}^{C1})}{dt} = \underbrace{-\frac{CL_{ADC}}{V_{ADC}^{C1}} \times Ab_{bi,mj}^{C1}}_{\text{To clearance of ADC}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_{bi,mj}^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_{bi,mj}^{C2}}_{\text{From peripheral space}}$$

$$\underbrace{-\left(\frac{Ab_{bi,mj}^{C1}}{V_{ADC}^{C1}} - \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}}\right) \times \frac{V^{tumor}}{BW} \times \left(\frac{2 \times P_{ADC} \times R_{cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2}\right)}_{\text{To tumor extracellular space}}$$

$$\underbrace{+K_{on}^{Ab,Drug} \times (max - i + 1 - j) \times Ab_{bi-1,mj}^{C1} \times Drug_f^{C1}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi,mj}^{C1}}_{\text{To unbinding of drug}}$$

$$\underbrace{+K_{on}^{Ab,Meta} \times (max - i - j + 1) \times Ab_{bi,mj-1}^{C1} \times Meta1_f^{C1}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times Ab_{bi,mj}^{C1}}_{\text{To unbinding of metabolite}}$$

Concentration (nM) of free (unbound) Drug in central compartment/plasma

$$\begin{aligned}
 \frac{d(\text{Drug}_f^{C1})}{dt} = & \underbrace{-\frac{CL_{Drug}}{V_{Drug}^{C1}} \times \text{Drug}_f^{C1}}_{\text{To clearance of drug}} - \underbrace{\frac{CLD_{Drug}}{V_{Drug}^{C1}} \times \text{Drug}_f^{C1}}_{\text{To peripheral space}} + \underbrace{\frac{CLD_{Drug}}{V_{Drug}^{C1}} \times \text{Drug}_f^{C2}}_{\text{From peripheral space}} + \underbrace{\frac{\sum_{i=1, j=0}^{\max} CL_{ADC} \times i \times \frac{Ab_{bi,mj}^{C1}}{V_{ADC}^{C1}}}{V_{Drug}^{C1}}}_{\text{From clearance of Ab bound to i Protacs}} \\
 & - \underbrace{\left(\text{Drug}_f^{C1} - \frac{\text{Drug}_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}} \right) \times \frac{V_{tumor}}{V_{Drug}^{C1} \times BW} \times \left(\frac{2 \times P_{Drug} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{Drug}}{R_{Tumor}^2} \right)}_{\text{To tumor extracellular space}} + \underbrace{\frac{K_{dec}^{ADC} \times \left(\sum_{i=0}^2 ADC_{bi}^{C1} + \sum_{j=1}^2 ADC_{mj}^{C1} + ADC_{b1,m}^{C1} \right)}{V_{Drug}^{C1}}}_{\text{From non-specific deconjugation of ADC}} \\
 & - \underbrace{K_{on,off}^{Drug,ex,ntp} \times (1 - f_{ub}^{ex}) \times \text{Drug}_f^{C1} + K_{on,off}^{Drug,ex,ntp} \times f_{ub}^{ex} \times \text{Drug}_{b,ntp}^{C1} - K_{met}^{Drug,C1} \times \text{Drug}_f^{C1}}_{\text{To and from protein binding}} + \underbrace{\frac{CL_{ADC} \times \overline{DAR} \times \left(\sum_{i=0}^2 ADC_{bi}^{C1} + \sum_{j=1}^2 ADC_{mj}^{C1} + ADC_{b1,m}^{C1} \right)}{V_{ADC}^{C1}}}_{\text{From clearance of ADC}} \\
 & - \underbrace{\sum_{i,j=0, i+j < \max}^{\max-1} K_{on}^{Ab,Drug} \times (\max - i - j) \times \frac{Ab_{bi,mj}^{C1}}{V_{Drug}^{C1}} \times \text{Drug}_f^{C1}}_{\text{To binding to antibody}} + \underbrace{\sum_{i=1, j=0, i+j \leq \max}^{\max} K_{off}^{Ab,Drug} \times \frac{Ab_{bi,mj}^{C1}}{V_{Drug}^{C1}}}_{\text{From unbinding of antibody}} \\
 & - K_{on}^{Ab,Drug} \times \left(2 \times \frac{ADC_f^{C1}}{V_{Drug}^{C1}} + \frac{ADC_{b1}^{C1}}{V_{Drug}^{C1}} + \frac{ADC_{m1}^{C1}}{V_{Drug}^{C1}} \right) \times \text{Drug}_f^{C1} + K_{off}^{Ab,Drug} \times \left(\frac{ADC_{b1}^{C1}}{V_{Drug}^{C1}} + \frac{ADC_{b2}^{C1}}{V_{Drug}^{C1}} + \frac{ADC_{b1,m1}^{C1}}{V_{Drug}^{C1}} \right)
 \end{aligned}$$

Concentration (nM) of drug bound to unspecific protein in central compartment/plasma

$$\frac{d(Drug_{b,ntp}^{C1})}{dt} = \underbrace{K_{on,off}^{Drug,ex,ntp} \times (1 - f_{ub}^{ex}) \times Drug_f^{C1}}_{\text{To unspecific protein binding}} - \underbrace{K_{on,off}^{Drug,ex,ntp} \times f_{ub}^{ex} \times Drug_{b,ntp}^{C1}}_{\text{To unspecific protein unbinding}}$$

Units: $\frac{nmol}{l \times h} = \frac{1}{h} \times 1 \times \frac{nmol}{l} - \frac{1}{h} \times 1 \times \frac{nmol}{l}$

Concentration (nM) of free (unbound) Metabolite1 in central compartment/plasma

$$\frac{d(Meta1_f^{C1})}{dt} = \underbrace{-\frac{CL_{Meta}}{V_{Meta}^{C1}} \times Meta1_f^{C1}}_{\text{To clearance}} + \underbrace{\frac{\sum_{i=0, j=1}^{max} CL_{ADC} \times j \times \frac{Ab_{bi,mj}^{C1}}{V_{ADC}^{C1}}}{V_{Meta}^{C1}}}_{\text{From clearance of Ab bound to j Metabolites1}} + \underbrace{K_{met}^{Drug,C1} \times Drug_f^{C1}}_{\text{From metabolism}}$$

$$\underbrace{-\left(Meta1_f^{C1} - \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}\right) \times \frac{V_{tumor}}{V_{Meta}^{C1} \times BW} \times \left(\frac{2 \times P_{Meta} \times R_{cap}}{R_{Krogh}^2} + \frac{6 \times D_{Meta}}{R_{Tumor}^2}\right)}_{\text{To tumor extracellular space}}$$

$$\underbrace{-\sum_{i,j=0, i+j < max}^{max-1} K_{on}^{Ab,Meta} \times (max - i - j) \times \frac{Ab_{bi,mj}^{C1}}{V_{Meta}^{C1}} \times Meta1_f^{C1}}_{\text{To binding to antibody}} + \underbrace{\sum_{i=0, j=1, i+j \leq max}^{max} K_{off}^{Ab,Meta} \times \frac{Ab_{bi,mj}^{C1}}{V_{Meta}^{C1}}}_{\text{From unbinding of antibody}}$$

$$-K_{on}^{Ab,Meta} \times \left(2 \times \frac{ADC_f^{C1}}{V_{Meta}^{C1}} + \frac{ADC_{b1}^{C1}}{V_{Meta}^{C1}} + \frac{ADC_{m1}^{C1}}{V_{Meta}^{C1}}\right) \times Meta1_f^{C1} + K_{off}^{Ab,Meta} \times \left(\frac{ADC_{m1}^{C1}}{V_{Meta}^{C1}} + \frac{ADC_{m2}^{C1}}{V_{Meta}^{C1}} + \frac{ADC_{b1,m1}^{C1}}{V_{Meta}^{C1}}\right)$$

Concentration (nM) of free Metabolite2 in central compartment/plasma

$$\frac{d(Meta2_f^{C1})}{dt} = \underbrace{-\frac{CL_{Meta}}{V_{Meta}^{C1}} \times Meta2_f^{C1}}_{\text{To clearance}} + \underbrace{K_{met}^{Drug,C1} \times Drug_f^{C1}}_{\text{From metabolism}}$$

$$\underbrace{-\left(Meta2_f^{C1} - \frac{Meta2_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}\right) \times \frac{V_{tumor}}{V_{Meta}^{C1} \times BW} \times \left(\frac{2 \times P_{Meta} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{Meta}}{R_{Tumor}^2}\right)}_{\text{To tumor extracellular space}}$$

Units:

$$\frac{nmol}{l \times h} = -\frac{l}{h} / kg \times \frac{nmol}{l} - \frac{l}{h} / kg \times \frac{nmol}{l} + \frac{l}{h} / kg \times \frac{nmol}{l} + \frac{1}{h} \times \frac{nmol}{kg} \times 1 + \frac{l}{h} / kg \times 1 \times \frac{nmol/kg}{l/kg}$$

$$- \left(\frac{nmol}{l} - \frac{nmol}{l \times 1}\right) \times \frac{l}{l/kg \times kg} \times \left(\frac{\frac{um}{h} \times um}{um^2} + \frac{cm^2/h}{cm^2}\right) \frac{1}{h} \times \frac{nmol}{l} + \frac{1}{h} \times 1 \times \frac{nmol}{l} + \frac{1}{h} \times 1 \times \frac{1 \times nmol}{kg \times \frac{l}{kg}} - \frac{1}{h} \times \frac{l \times 1}{kg \times \frac{l}{kg}} \times \frac{nmol}{l}$$

Amount (nmol/kg) of free ADC (bound to 0 Protacs) in peripheral compartment

$$\frac{d(ADC_f^{C2})}{dt} = \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times ADC_f^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times ADC_f^{C2}}_{\text{To central space}}$$

From central space To central space

$$\underbrace{-K_{on}^{Ab,Drug} \times 2 \times ADC_f^{C2} \times Drug_f^{C2}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times ADC_{b1}^{C2}}_{\text{From unbinding of drug}}$$

To binding to drug

From unbinding of drug

Units:

$$\frac{nmol}{kg \times h} = \frac{l/kg}{h} \times \frac{nmol}{kg} - \frac{l/kg}{h} \times nmol/kg$$

Amount (nmol/kg) of ADC bound to 1 Protac in peripheral compartment

$$\frac{d(ADC_{b1}^{C2})}{dt} = \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times ADC_{b1}^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times ADC_{b1}^{C2}}_{\text{To central space}}$$

$$\underbrace{-K_{on}^{Ab,Drug} \times ADC_{b1}^{C2} \times Drug_f^{C2}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times ADC_{b2}^{C2}}_{\text{From unbinding of drug}}$$

$$\underbrace{+K_{on}^{Ab,Drug} \times 2 \times ADC_f^{C2} \times Drug_f^{C2}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times ADC_{b1}^{C2}}_{\text{To unbinding of drug}}$$

Units:

$$\frac{nmol}{kg \times h} = \frac{l}{h}/kg \times \frac{nmol}{kg} - \frac{l}{h}/kg \times nmol/kg$$

Amount (nmol/kg) of ADC bound to 2 Protacs in peripheral compartment

$$\frac{d(ADC_{b2}^{C2})}{dt} = \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times ADC_{b2}^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times ADC_{b2}^{C2}}_{\text{To central space}}$$

$$+ \underbrace{K_{on}^{Ab,Drug} \times ADC_{b1}^{C2} \times Drug_f^{C2}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times ADC_{b2}^{C2}}_{\text{To unbinding of drug}}$$

Units:

$$\frac{nmol}{kg \times h} = \frac{l/kg}{l/kg} \times \frac{nmol}{kg} - \frac{l/kg}{l/kg} \times nmol/kg$$

Amount (nmol/kg) of ADC bound to 1 Metabolite1 in peripheral compartment

$$\frac{d(ADC_{m1}^{C2})}{dt} = \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times ADC_{m1}^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times ADC_{m1}^{C2}}_{\text{To central space}}$$

From central space To central space

$$\underbrace{-K_{on}^{Ab,Drug} \times ADC_{m1}^{C2} \times Drug_f^{C2}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times ADC_{b1,m1}^{C2}}_{\text{From unbinding of drug}}$$

To binding to drug

From unbinding of drug

Units:

$$\frac{nmol}{kg \times h} = \frac{l/kg}{h} \times \frac{nmol}{kg} - \frac{l/kg}{h} \times nmol/kg$$

Amount (nmol/kg) of ADC bound to 2 Metabolites¹ in peripheral compartment

$$\frac{d(ADC_{m2}^{C2})}{dt} = \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times ADC_{m2}^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times ADC_{m2}^{C2}}_{\text{To central space}}$$

Units:

$$\frac{nmol}{kg \times h} = \frac{l/kg}{l/kg} \times \frac{nmol}{kg} - \frac{l/kg}{l/kg} \times nmol/kg$$

Amount (nmol/kg) of ADC bound to 1 Protac and 1 Metabolite1 in peripheral compartment

$$\frac{d(ADC_{b1,m1}^{C2})}{dt} = \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times ADC_{b1,m1}^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times ADC_{b1,m1}^{C2}}_{\text{To central space}}$$

$$\underbrace{+K_{on}^{Ab,Drug} \times ADC_{m1}^{C2} \times Drug_f^{C2}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times ADC_{b1,m1}^{C2}}_{\text{To unbinding of drug}}$$

Amount (nmol/kg) of free Antibody (bound to 0 Protacs) in peripheral compartment

$$\frac{d (Ab_f^{C2})}{dt} = \frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_f^{C1} - \frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_f^{C2}$$

From central space To central space

$$-K_{on}^{Ab,Drug} \times max \times Ab_f^{C2} \times Drug_f^{C2} + K_{off}^{Ab,Drug} \times Ab_{b1}^{C2}$$

To binding to drug

From unbinding of drug

Units:

$$\frac{nmol}{kg \times h} = \frac{\frac{l}{h}/kg}{l/kg} \times \frac{nmol}{kg} - \frac{\frac{l}{h}/kg}{l/kg} \times nmol/kg$$

Amount (nmol/kg) of Antibody bound to i Protacs in peripheral compartment , $i = 1,2,3$

$$\frac{d (Ab_{bi}^{C2})}{dt} = \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_{bi}^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_{bi}^{C2}}_{\text{To central space}}$$

$$\underbrace{-K_{on}^{Ab,Drug} \times (max - i) \times Ab_{bi}^{C2} \times Drug_f^{C2}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi+1}^{C2}}_{\text{From unbinding of drug}}$$

$$\underbrace{+K_{on}^{Ab,Drug} \times (max - i + 1) \times Ab_{i-1}^{C2} \times Drug_f^{C2}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi}^{C2}}_{\text{To unbinding of drug}}$$

Units:

$$\frac{nmol}{kg \times h} = \frac{\frac{l}{h}/kg}{l/kg} \times \frac{nmol}{kg} - \frac{\frac{l}{h}/kg}{l/kg} \times nmol/kg$$

Amount (nmol/kg) of Antibody bound to 4 Protacs in peripheral compartment

$$\frac{d (Ab_{b4}^{C2})}{dt} = \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_{b4}^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_{b4}^{C2}}_{\text{To central space}}$$

$$\underbrace{+K_{on}^{Ab,Drug} \times Ab_{b3}^{C2} \times Drug_f^{C2}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times Ab_{b4}^{C2}}_{\text{To unbinding of drug}}$$

Units:

$$\frac{nmol}{kg \times h} = \frac{\frac{l}{h}/kg}{l/kg} \times \frac{nmol}{kg} - \frac{\frac{l}{h}/kg}{l/kg} \times nmol/kg$$

Amount (nmol/kg) of Antibody bound to j Metabolites1 in peripheral compartment, j = 1,2,3

$$\frac{d (Ab_{mj}^{C2})}{dt} = \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_{mj}^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_{mj}^{C2}}_{\text{To central space}}$$

$$\underbrace{-K_{on}^{Ab,Drug} \times (max - j) \times Ab_{mj}^{C2} \times Drug_f^{C2}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times Ab_{b1,mj}^{C2}}_{\text{From unbinding of drug}}$$

Units:

$$\frac{nmol}{kg \times h} = \frac{\frac{l}{h}/kg}{l/kg} \times \frac{nmol}{kg} - \frac{\frac{l}{h}/kg}{l/kg} \times nmol/kg$$

Amount (nmol/kg) of Antibody bound to 4 Metabolites¹ in peripheral compartment

$$\frac{d (Ab_{m4}^{C2})}{dt} = \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_{m4}^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_{m4}^{C2}}_{\text{To central space}}$$

Units:

$$\frac{\text{nmol}}{\text{kg} \times \text{h}} = \frac{\frac{\text{l}}{\text{h}}/\text{kg}}{\text{l}/\text{kg}} \times \frac{\text{nmol}}{\text{kg}} - \frac{\frac{\text{l}}{\text{h}}/\text{kg}}{\text{l}/\text{kg}} \times \text{nmol}/\text{kg}$$

Amount (nmol/kg) of Antibody bound to i Protac and j Metabolites1 in peripheral compartment, $i = 1,2$ and $j = 1,2$
with $i + j < \max$

$$\begin{aligned}
 \frac{d(Ab_{bi,mj}^{C2})}{dt} = & \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_{bi,mj}^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_{bi,mj}^{C2}}_{\text{To central space}} \\
 & \underbrace{-K_{on}^{Ab,Drug} \times (\max - i - j) \times Ab_{bi,mj}^{C2} \times Drug_f^{C2}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi+1,mj}^{C2}}_{\text{From unbinding of drug}} \\
 & \underbrace{+K_{on}^{Ab,Drug} \times (\max - i + 1 - j) \times Ab_{bi-1,mj}^{C2} \times Drug_f^{C2}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi,mj}^{C2}}_{\text{To unbinding of drug}}
 \end{aligned}$$

Amount (nmol/kg) of Antibody bound to i Protac and j Metabolites1 in peripheral compartment, i = 1,2,3 and j = 1,2,3
with i + j = max

$$\frac{d(Ab_{bi,mj}^{C2})}{dt} = \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C1}} \times Ab_{bi,mj}^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{ADC}}{V_{ADC}^{C2}} \times Ab_{bi,mj}^{C2}}_{\text{To central space}}$$

$$+ \underbrace{K_{on}^{Ab,Drug} \times (max - i + 1 - j) \times Ab_{bi-1,mj}^{C2} \times Drug_f^{C2}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi,mj}^{C2}}_{\text{To unbinding of drug}}$$

Concentration (nM) of free drug in peripheral compartment

$$\begin{aligned}
 \frac{d(\text{Drug}_f^{C2})}{dt} = & \underbrace{\frac{CLD_{Drug}}{V_{Drug}^{C2}} \times \text{Drug}_f^{C1}}_{\text{From central space}} - \underbrace{\frac{CLD_{Drug}}{V_{Drug}^{C2}} \times \text{Drug}_f^{C2}}_{\text{To central space}} \\
 & - \underbrace{\sum_{i,j=0,i+j < \max}^{max-1} K_{on}^{Ab,Drug} \times (\max - i - j) \times \frac{Ab_{bi,mj}^{C2}}{V_{Drug}^{C2}} \times \text{Drug}_f^{C2}}_{\text{To binding to antibody}} + \underbrace{\sum_{i=1,j=0,i+j \leq \max}^{max} K_{off}^{Ab,Drug} \times \frac{Ab_{bi,mj}^{C2}}{V_{Drug}^{C2}}}_{\text{From unbinding of antibody}} \\
 & - K_{on}^{Ab,Drug} \times \left(2 \times \frac{ADC_f^{C2}}{V_{Drug}^{C2}} + \frac{ADC_{b1}^{C2}}{V_{Drug}^{C2}} + \frac{ADC_{m1}^{C2}}{V_{Drug}^{C2}} \right) \times \text{Drug}_f^{C2} + K_{off}^{Ab,Drug} \times \left(\frac{ADC_{b1}^{C2}}{V_{Drug}^{C2}} + \frac{ADC_{b2}^{C2}}{V_{Drug}^{C2}} + \frac{ADC_{b1,m1}^{C2}}{V_{Drug}^{C2}} \right)
 \end{aligned}$$

Units:

$$\frac{nmol}{l \times h} = \frac{l}{h/kg} \times \frac{nmol}{l} - \frac{l}{h/kg} \times \frac{nmol}{l}$$

Concentration (nM) of free ADC (bound to 0 Protacs) in tumor extracellular space

$$\begin{aligned}
 \frac{d(ADC_f^{ex})}{dt} = & \underbrace{\left(\frac{ADC_f^{C1}}{V_{ADC}^{C1}} - \frac{ADC_f^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{From central space}} + \underbrace{K_{off}^{ADC,cell,ag} \times ADC_{f,b,ag}^{cell} \times \frac{NC^{tumor} \times SF}{V^{tumor}}}_{\text{From unbinding of ADC to receptors on tumor cell}} \\
 & - \underbrace{K_{on}^{ADC,cell,ag} \times \frac{ADC_f^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{\max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{\max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq \max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} - ADC_{b1,m1,b,ag}^{cell} \right)}_{\text{To binding of ADC to receptors on tumor cell}} \\
 & + \underbrace{\frac{NC^{tumor} \times SF}{V^{tumor}} + \frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times (ADC_{f,b,ag}^{cell}) \times \frac{SF}{V^{tumor}}}_{\text{From intracellular content of dying cells}} - \underbrace{K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times ADC_f^{ex}}_{\text{To pinocytosis}} \\
 & - \underbrace{K_{on}^{Ab,Drug} \times 2 \times \frac{ADC_f^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V^{tumor} \times \varepsilon^{Drug}}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times \frac{ADC_{b1}^{ex}}{\varepsilon^{ADC}}}_{\text{From unbinding of drug}} - \underbrace{K_{on}^{Ab,Meta} \times 2 \times \frac{ADC_f^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{V^{tumor} \times \varepsilon^{Meta}}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times \frac{ADC_{m1}^{ex}}{\varepsilon^{ADC}}}_{\text{From unbinding of metabolite}}
 \end{aligned}$$

Concentration (nM) of ADC bound to 1 Protac in tumor extracellular space

$$\begin{aligned}
 \frac{d(ADC_{b1}^{ex})}{dt} = & \underbrace{\left(\frac{ADC_{b1}^{C1}}{V_{ADC}^{C1}} - \frac{ADC_{b1}^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{From central space}} + K_{off}^{ADC,cell,ag} \times ADC_{b1,b,ag}^{cell} \times \frac{NC^{tumor} \times SF}{V^{tumor}} \\
 & + \underbrace{\left(-K_{on}^{ADC,cell,ag} \times \frac{ADC_{b1}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} - ADC_{b1,m1,b,ag}^{cell} \right) \right)}_{\text{Binding and unbinding of ADC to receptors on tumor cell}} \\
 & \times \frac{NC^{tumor} \times SF}{V^{tumor}} + \underbrace{\frac{1}{\tau} \times V_{dyl,3,mm3}^{tumor} \times 10^5 \times (ADC_{b1,b,ag}^{cell} + ADC_{b1}^{cell,lyso}) \times \frac{SF}{V^{tumor}}}_{\text{From intracellular content of dying cells}} - \underbrace{K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times ADC_{b1}^{ex}}_{\text{To pinocytosis}} \\
 & \underbrace{-K_{on}^{Ab,Drug} \times \frac{ADC_{b1}^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V^{tumor} \times \varepsilon^{Drug}}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times \frac{ADC_{b2}^{ex}}{\varepsilon^{ADC}}}_{\text{From unbinding of drug}} + \underbrace{K_{on}^{Ab,Drug} \times 2 \times \frac{ADC_f^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V^{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} \\
 & \underbrace{-K_{off}^{Ab,Drug} \times \frac{ADC_{b1}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of drug}} - \underbrace{K_{on}^{Ab,Meta} \times \frac{ADC_{b1}^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{V^{tumor} \times \varepsilon^{Meta}}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times \frac{ADC_{b1,m1}^{ex}}{\varepsilon^{ADC}}}_{\text{From unbinding of metabolite}}
 \end{aligned}$$

Concentration (nM) of ADC bound to 2 Protacs in tumor extracellular space

$$\begin{aligned}
 \frac{d(ADC_{b2}^{ex})}{dt} = & \underbrace{\left(\frac{ADC_{b2}^{C1}}{V_{ADC}^{C1}} - \frac{ADC_{b2}^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{From central space}} + K_{off}^{ADC,cell,ag} \times ADC_{b2,b,ag}^{cell} \times \frac{NC^{tumor} \times SF}{V^{tumor}} \\
 & + \underbrace{\left(-K_{on}^{ADC,cell,ag} \times \frac{ADC_{b2}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} - ADC_{b1,m1,b,ag}^{cell} \right) \right)}_{\text{Binding and unbinding of ADC to receptors on tumor cell}} \\
 & \times \frac{NC^{tumor} \times SF}{V^{tumor}} + \underbrace{\frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times (ADC_{b2,b,ag}^{cell} + ADC_{b2}^{cell,lyso}) \times \frac{SF}{V^{tumor}}}_{\text{From intracellular content of dying cells}} - \underbrace{K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times ADC_{b2}^{ex}}_{\text{To pinocytosis}} \\
 & + \underbrace{K_{on}^{Ab,Drug} \times \frac{ADC_{b1}^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V^{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times \frac{ADC_{b2}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of drug}}
 \end{aligned}$$

Concentration (nM) of ADC bound to 1 Metabolite1 in tumor extracellular space

$$\frac{d(ADC_{m1}^{ex})}{dt} = \left(\frac{ADC_{m1}^{C1}}{V_{ADC}^{C1}} - \frac{ADC_{m1}^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)$$

From central space

$$+ \left(-K_{on}^{ADC,cell,ag} \times \frac{ADC_{m1}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} \right) \right.$$

Binding and unbinding of ADC to receptors on tumor cell

$$\times \frac{NC^{tumor} \times SF}{V^{tumor}} + \frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times (ADC_{m1,b,ag}^{cell} + ADC_{m1}^{cell,lyso}) \times \frac{SF}{V^{tumor}} - K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times ADC_{m1}^{ex}$$

From intracellular content of dying cells

To pinocytosis

$$-K_{on}^{Ab,Drug} \times \frac{ADC_{m1}^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V^{tumor} \times \varepsilon^{Drug}} + K_{off}^{Ab,Drug} \times \frac{ADC_{b1,m1}^{ex}}{\varepsilon^{ADC}} + K_{on}^{Ab,Meta} \times 2 \times \frac{ADC_f^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{V^{tumor} \times \varepsilon^{Meta}}$$

To binding to drug

From unbinding of drug

From binding to metabolite

$$-K_{off}^{Ab,Meta} \times \frac{ADC_{m1}^{ex}}{\varepsilon^{ADC}} - K_{on}^{Ab,Meta} \times \frac{ADC_{m1}^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{V^{tumor} \times \varepsilon^{Meta}} + K_{off}^{Ab,Meta} \times \frac{ADC_{m2}^{ex}}{\varepsilon^{ADC}}$$

To unbinding of metabolite

To binding to metabolite

From unbinding of metabolite

Concentration (nM) of ADC bound to 2 Metabolites¹ in tumor extracellular space

$$\begin{aligned}
 \frac{d(ADC_{m2}^{ex})}{dt} = & \underbrace{\left(\frac{ADC_{m2}^{C1}}{V_{ADC}^{C1}} - \frac{ADC_{m2}^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{From central space}} \\
 & + \underbrace{\left(-K_{on}^{ADC,cell,ag} \times \frac{ADC_{m2}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} \right) \right.}_{\text{Binding and unbinding of ADC to receptors on tumor cell}} \\
 & \times \frac{NC^{tumor} \times SF}{V^{tumor}} + \underbrace{\frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times (ADC_{m2,b,ag}^{cell} + ADC_{m2}^{cell,lyso}) \times \frac{SF}{V^{tumor}}}_{\text{From intracellular content of dying cells}} - \underbrace{K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times ADC_{m2}^{ex}}_{\text{To pinocytosis}} \\
 & + \underbrace{K_{on}^{Ab,Meta} \times \frac{ADC_{m1}^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{V^{tumor} \times \varepsilon^{Meta}}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times \frac{ADC_{m2}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of metabolite}}
 \end{aligned}$$

Concentration (nM) of ADC bound to 1 Protac and 1 Metabolite1 in tumor extracellular space

$$\begin{aligned}
 \frac{d(ADC_{b1,m1}^{ex})}{dt} = & \underbrace{\left(\frac{ADC_{b1,m1}^{C1}}{V_{ADC}^{C1}} - \frac{ADC_{b1,m1}^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{From central space}} \\
 & + \underbrace{\left(-K_{on}^{ADC,cell,ag} \times \frac{ADC_{b1,m1}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} \right) \right.}_{\text{Binding and unbinding of ADC to receptors on tumor cell}} \\
 & \times \frac{NC^{tumor} \times SF}{V_{tumor}} + \underbrace{\frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times (ADC_{b1,m1,b,ag}^{cell} + ADC_{b1,m1}^{cell,lyso}) \times \frac{SF}{V_{tumor}}}_{\text{From intracellular content of dying cells}} - \underbrace{K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times ADC_{b1,m1}^{ex}}_{\text{To pinocytosis}} \\
 & + \underbrace{K_{on}^{Ab,Drug} \times \frac{ADC_{m1}^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times \frac{ADC_{b1,m1}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of drug}} \\
 & + \underbrace{K_{on}^{Ab,Meta} \times \frac{ADC_{b1}^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times \frac{ADC_{b1,m1}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of metabolite}}
 \end{aligned}$$

Concentration (nM) of free Antibody (bound to 0 Protacs) in tumor extracellular space

$$\begin{aligned}
 \frac{d(Ab_f^{ex})}{dt} = & \left(\frac{Ab_f^{C1}}{V_{ADC}^{C1}} - \frac{Ab_f^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right) \\
 & + \left(-K_{on}^{ADC,cell,ag} \times \frac{Ab_f^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} - ADC_{b1,m1,b,ag}^{cell} \right) \right. \\
 & \left. + K_{off}^{ADC,cell,ag} \times Ab_{f,b,ag}^{cell} \right) \\
 & \times \frac{NC^{tumor} \times SF}{V_{tumor}} + \frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times (Ab_{f,b,ag}^{cell}) \times \frac{SF}{V_{tumor}} - K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times Ab_f^{ex} \\
 & - K_{on}^{Ab,Drug} \times max \times \frac{Ab_f^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}} + K_{off}^{Ab,Drug} \times \frac{Ab_{b1}^{ex}}{\varepsilon^{ADC}} - K_{on}^{Ab,Meta} \times max \times \frac{Ab_f^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}} + K_{off}^{Ab,Meta} \times \frac{Ab_{m1}^{ex}}{\varepsilon^{ADC}}
 \end{aligned}$$

From central space

Binding and unbinding of ADC to receptors on tumor cell

From intracellular content of dying cells

To pinocytosis

To binding to drug

From unbinding of drug

To binding to metabolite

From unbinding of metabolite

Concentration (nM) of Antibody bound to i Protacs in tumor extracellular space, i = 1,2,3

$$\begin{aligned}
 \frac{d(Ab_{bi}^{ex})}{dt} = & \underbrace{\left(\frac{Ab_{bi}^{C1}}{V_{ADC}^{C1}} - \frac{Ab_{bi}^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right) + K_{off}^{ADC,cell,ag} \times Ab_{bi,b,ag}^{cell} \times \frac{NC^{tumor} \times SF}{V_{tumor}}}_{\text{From central space}} \\
 & + \underbrace{\left(-K_{on}^{ADC,cell,ag} \times \frac{Ab_{bi}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} - ADC_{b1,m1,b,ag}^{cell} \right) \right.}_{\text{Binding and unbinding of ADC to receptors on tumor cell}} \\
 & \times \frac{NC^{tumor} \times SF}{V_{tumor}} + \underbrace{\frac{1}{\tau} \times V_{dyl,3,mm3}^{tumor} \times 10^5 \times (Ab_{bi,b,ag}^{cell} + Ab_{bi}^{cell,lyso}) \times \frac{SF}{V_{tumor}}}_{\text{From intracellular content of dying cells}} - \underbrace{K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times Ab_{bi}^{ex}}_{\text{To pinocytosis}} \\
 & - \underbrace{K_{on}^{Ab,Drug} \times (max - i) \times \frac{Ab_{bi}^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times \frac{Ab_{bi+1}^{ex}}{\varepsilon^{ADC}}}_{\text{From unbinding of drug}} + \underbrace{K_{on}^{Ab,Drug} \times (max - i + 1) \times \frac{Ab_{bi-1}^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} \\
 & - \underbrace{K_{off}^{Ab,Drug} \times \frac{Ab_{bi}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of drug}} - \underbrace{K_{on}^{Ab,Meta} \times (max - i) \times \frac{Ab_{bi}^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times \frac{Ab_{bi,m1}^{ex}}{\varepsilon^{ADC}}}_{\text{From unbinding of metabolite}}
 \end{aligned}$$

Concentration (nM) of Antibody bound to 4 Protacs in tumor extracellular space

$$\begin{aligned}
 \frac{d(Ab_{b4}^{ex})}{dt} = & \underbrace{\left(\frac{Ab_{b4}^{C1}}{V_{ADC}^{C1}} - \frac{Ab_{b4}^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{From central space}} \\
 & + \underbrace{\left(-K_{on}^{ADC,cell,ag} \times \frac{Ab_{b4}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} - ADC_{b1,m1,b,ag}^{cell} \right) \right.}_{\text{Binding and unbinding of ADC to receptors on tumor cell}} \\
 & \left. + K_{off}^{ADC,cell,ag} \times Ab_{b4,b,ag}^{cell} \right) \\
 & \times \underbrace{\frac{NC^{tumor} \times SF}{V^{tumor}} + \frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times (Ab_{b4,b,ag}^{cell} + Ab_{b4}^{cell,lyso}) \times \frac{SF}{V^{tumor}}}_{\text{From intracellular content of dying cells}} - \underbrace{K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times Ab_{b4}^{ex}}_{\text{To pinocytosis}} \\
 & + \underbrace{K_{on}^{Ab,Drug} \times \frac{Ab_{b3}^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V^{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times \frac{Ab_{b4}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of drug}}
 \end{aligned}$$

Concentration (nM) of Antibody bound to j Metabolites1 in tumor extracellular space, j = 1,2,3

$$\frac{d(Ab_{mj}^{ex})}{dt} = \left(\frac{Ab_{mj}^{C1}}{V_{ADC}^{C1}} - \frac{Ab_{mj}^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)$$

From central space

$$+ \left(-K_{on}^{ADC,cell,ag} \times \frac{Ab_{mj}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj}^{ce} \right) \right)$$

Binding and unbinding of ADC to receptors on tumor cell

$$\times \frac{NC^{tumor} \times SF}{V_{tumor}} + \frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times \left(Ab_{mj,b,ag}^{cell} + Ab_{mj}^{cell,lyso} \right) \times \frac{SF}{V_{tumor}} - K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times Ab_{mj}^{ex}$$

From intracellular content of dying cells

To pinocytosis

$$-K_{on}^{Ab,Drug} \times (max - j) \times \frac{Ab_{mj}^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}} + K_{off}^{Ab,Drug} \times \frac{Ab_{b1,mj}^{ex}}{\varepsilon^{ADC}} + K_{on}^{Ab,Meta} \times (max - j + 1) \times \frac{Ab_{mj-1}^{ex}}{\varepsilon^{ADC}} \times \frac{M}{V_{tumor}}$$

To binding to drug

From unbinding of drug

From binding to metabolite

$$-K_{off}^{Ab,Meta} \times \frac{Ab_{mj}^{ex}}{\varepsilon^{ADC}} - K_{on}^{Ab,Meta} \times (max - j) \times \frac{Ab_{mj}^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}} + K_{off}^{Ab,Meta} \times \frac{Ab_{mj+1}^{ex}}{\varepsilon^{ADC}}$$

To unbinding of metabolite

To binding to metabolite

From unbinding of metabolite

Concentration (nM) of Antibody bound to 4 Metabolites¹ in tumor extracellular space

$$\begin{aligned}
 \frac{d(Ab_{m4}^{ex})}{dt} = & \underbrace{\left(\frac{Ab_{m4}^{C1}}{V_{ADC}^{C1}} - \frac{Ab_{m4}^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{From central space}} \\
 & + \underbrace{\left(-K_{on}^{ADC,cell,ag} \times \frac{Ab_{m4}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj}^{cell} \right) \right.}_{\text{Binding and unbinding of ADC to receptors on tumor cell}} \\
 & \times \frac{NC^{tumor} \times SF}{V^{tumor}} + \underbrace{\frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times (Ab_{m4,b,ag}^{cell} + Ab_{m4}^{cell,lyso}) \times \frac{SF}{V^{tumor}}}_{\text{From intracellular content of dying cells}} - \underbrace{K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times Ab_{m4}^{ex}}_{\text{To pinocytosis}} \\
 & + \underbrace{K_{on}^{Ab,Meta} \times \frac{Ab_{m3}^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{V^{tumor} \times \varepsilon^{Meta}}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times \frac{Ab_{m4}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of metabolite}}
 \end{aligned}$$

Concentration (nM) of Antibody bound to i Protac and j Metabolites1 in tumor extracellular space, i = 1,2 and j = 1,2

$$\begin{aligned}
 \frac{d(Ab_{bi,mj}^{ex})}{dt} = & \underbrace{\left(\frac{Ab_{bi,mj}^{C1}}{V_{ADC}^{C1}} - \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{From central space}} \\
 & + \left(-K_{on}^{ADC,cell,ag} \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} \right) \right. \\
 & \times \frac{NC^{tumor} \times SF}{V_{tumor}} + \underbrace{\frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times \left(Ab_{bi,mj,b,ag}^{cell} + Ab_{bi,mj}^{cell,lyso} \right) \times \frac{SF}{V_{tumor}}}_{\text{From intracellular content of dying cells}} - \underbrace{K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times Ab_{bi,mj}^{ex}}_{\text{To pinocytosis}} \\
 & - \underbrace{K_{on}^{Ab,Drug} \times (max - i - j) \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times \frac{Ab_{bi+1,mj}^{ex}}{\varepsilon^{ADC}}}_{\text{From unbinding of drug}} \\
 & + \underbrace{K_{on}^{Ab,Drug} \times (max - i + 1 - j) \times \frac{Ab_{bi-1,mj}^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of drug}} - \underbrace{K_{on}^{Ab,Meta} \times (max - i - j) \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}}}_{\text{To binding to metabolite}} \\
 & + \underbrace{K_{off}^{Ab,Meta} \times \frac{Ab_{bi,mj+1}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of drug}} + \underbrace{K_{on}^{Ab,Meta} \times (max - i - j + 1) \times \frac{Ab_{bi,mj-1}^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{To binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of drug}}
 \end{aligned}$$

Concentration (nM) of Antibody bound to i Protac and j Metabolites1 in tumor extracellular space, i = 1,2,3 and j = 1,2,3 with i + j = max

$$\begin{aligned}
 \frac{d(Ab_{bi,mj}^{ex})}{dt} = & \underbrace{\left(\frac{Ab_{bi,mj}^{C1}}{V_{ADC}^{C1}} - \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}} \right) \times \left(\frac{2 \times P_{ADC} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{ADC}}{R_{Tumor}^2} \right)}_{\text{From central space}} \\
 & + \underbrace{\left(-K_{on}^{ADC,cell,ag} \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} \right) \right.}_{\text{Binding and unbinding of ADC to receptors on tumor cell}} \\
 & \times \frac{NC^{tumor} \times SF}{V^{tumor}} + \underbrace{\frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times \left(Ab_{bi,mj,b,ag}^{cell} + Ab_{bi,mj}^{cell,lyso} \right) \times \frac{SF}{V^{tumor}}}_{\text{From intracellular content of dying cells}} - \underbrace{K_{pino}^{ADC,cell,lyso} \times \left(\frac{NCL^{tumor}}{\varepsilon^{ADC}} \right) \times Ab_{bi,mj}^{ex}}_{\text{To pinocytosis}} \\
 & + \underbrace{K_{on}^{Ab,Drug} \times (max - i + 1 - j) \times \frac{Ab_{bi-1,mj}^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{V^{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of drug}} \\
 & + \underbrace{K_{on}^{Ab,Meta} \times (max - i - j + 1) \times \frac{Ab_{bi,mj-1}^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{V^{tumor} \times \varepsilon^{Meta}}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}}}_{\text{To unbinding of metabolite}}
 \end{aligned}$$

Amount (nmol) of drug in tumor extracellular space

$$\begin{aligned}
 \frac{d(Drug_f^{ex})}{dt} = & \underbrace{\left(Drug_f^{C1} - \frac{Drug_f^{ex}}{V^{tumor} \times \varepsilon^{Drug}} \right) \times V^{tumor} \times \left(\frac{2 \times P_{Drug} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{Drug}}{R_{Tumor}^2} \right)}_{\text{From central space}} \\
 & + \underbrace{\left(K_{dec}^{ADC} \times \left(\sum_{i=0}^2 ADC_{bi,b,ag}^{cell} + \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} + ADC_{b1,m1,b,ag}^{cell} \right) \times \overline{DAR} + K_{out}^{Drug,ex} \times Drug_f^{cell,cyto} \right) \times NC^{tumor} \times SF}_{\text{Non-specific deconj. of ADC}} \\
 & - \underbrace{K_{in}^{Drug,ex} \times NC^{tumor} \times \left(\frac{V^{cell}}{V^{tumor} \times \varepsilon^{Drug}} \right) \times Drug_f^{ex}}_{\text{To influx into cells}} - \underbrace{K_{met}^{Drug,ex} \times \frac{Drug_f^{ex}}{\varepsilon^{Drug}}}_{\text{To metabolism}} + \underbrace{K_{dec}^{ADC} \times \frac{\left(\sum_{i=0}^2 ADC_{bi}^{ex} + \sum_{j=1}^2 ADC_{mj}^{ex} + ADC_{b1,m1}^{ex} \right)}{\varepsilon^{ADC}} \times \overline{DAR} \times V^{tumor}}_{\text{Efflux of drug from the cell}} \\
 & + \underbrace{\frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times \left(Drug_f^{cell,cyto} + Drug_{b,dt}^{cell,cyto} + Drug_f^{cell,lyso} \right) \times SF}_{\text{From intracellular content of dying cells}} - \underbrace{\sum_{i,j=0,i+j < max}^{max-1} K_{on}^{Ab,Drug} \times (max - i - j) \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}} \times \frac{Drug_f^{ex}}{\varepsilon^{Drug}}}_{\text{To binding to antibody}} \\
 & + \underbrace{\sum_{i=1,j=0,i+j \leq max}^{max} K_{off}^{Ab,Drug} \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}} \times V^{tumor}}_{\text{From unbinding of antibody}} - \underbrace{\sum_{i,j=0,i+j < max}^{max-1} K_{on}^{Ab,Drug} \times (max - i - j) \times Ab_{bi,mj,b,ag}^{cell} \times NC^{tumor} \times \frac{Drug_f^{ex}}{V^{tumor} \times \varepsilon^{Drug}} \times SF}_{\text{To binding to antibody bound to binding target on a single cell}} \\
 & + \underbrace{\sum_{i=1,j=0,i+j \leq max}^{max} K_{off}^{Ab,Drug} \times Ab_{bi,mj,b,ag}^{cell} \times NC^{tumor} \times SF}_{\text{From unbinding of antibody bound to binding target on a single cell}} - \underbrace{K_{on}^{Ab,Drug} \times \left(2 \times \frac{ADC_f^{ex}}{\varepsilon^{ADC}} + \frac{ADC_{b1}^{ex}}{\varepsilon^{ADC}} + \frac{ADC_{m1}^{ex}}{\varepsilon^{ADC}} \right) \times \frac{Drug_f^{ex}}{\varepsilon^{Drug}}}_{\text{To binding to antibody bound to binding target on a single cell}}
 \end{aligned}$$

Amount (nmol) of free (unbound) Metabolite1 in tumor extracellular space

$$\begin{aligned}
 \frac{d(Meta1_f^{ex})}{dt} = & \underbrace{K_{met}^{Drug,ex} \times \frac{Drug_f^{ex}}{\varepsilon^{Drug}}}_{\text{From metabolism}} + \underbrace{\left(Meta1_f^{c1} - \frac{Meta1_f^{ex}}{V^{tumor} \times \varepsilon^{Meta}} \right) \times V^{tumor} \times \left(\frac{2 \times P_{Meta} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{Meta}}{R_{Tumor}^2} \right)}_{\text{From central space}} \\
 & + \underbrace{K_{out}^{Meta,ex} \times Meta1_f^{cell,cyto} \times NC^{tumor} \times SF}_{\text{Fromm efflux of drug from the cell}} - \underbrace{K_{in}^{Meta,ex} \times NC^{tumor} \times \left(\frac{V^{cell}}{V^{tumor} \times \varepsilon^{Meta}} \right) \times Meta1_f^{ex}}_{\text{To influx into cells}} \\
 & + \underbrace{\frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times \left(Meta1_f^{cell,cyto} + Meta1_f^{cell,lyso} \right) \times SF}_{\text{From intracellular content of dying cells}} - \underbrace{\sum_{i,j=0,i+j < max}^{max-1} K_{on}^{Ab,Meta} \times (max - i - j) \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}} \times \frac{Meta1_f^{ex}}{\varepsilon^{Meta}}}_{\text{To binding to antibody}} \\
 & + \underbrace{\sum_{i=0,j=1,i+j \leq max}^{max} K_{off}^{Ab,Meta} \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}} \times V^{tumor}}_{\text{From unbinding of antibody}} - \underbrace{\sum_{i,j=0,i+j < max}^{max-1} K_{on}^{Ab,Meta} \times (max - i - j) \times Ab_{bi,mj,b,ag}^{cell} \times NC^{tumor} \times \frac{Meta1_f^{ex}}{V^{tumor} \times \varepsilon^{Meta}} \times SF}_{\text{To binding to antibody bound to binding target on a single cell}} \\
 & + \underbrace{\sum_{i=0,j=1,i+j \leq max}^{max} K_{off}^{Ab,Meta} \times Ab_{bi,mj,b,ag}^{cell} \times NC^{tumor} \times SF}_{\text{From unbinding of antibody bound to binding target on a single cell}} - \underbrace{K_{on}^{Ab,Meta} \times \left(2 \times \frac{ADC_f^{ex}}{\varepsilon^{ADC}} + \frac{ADC_{b1}^{ex}}{\varepsilon^{ADC}} + \frac{ADC_{m1}^{ex}}{\varepsilon^{ADC}} \right) \times \frac{Meta1_f^{ex}}{\varepsilon^{Meta}}}_{\text{To binding to antibody bound to binding target on a single cell}}
 \end{aligned}$$

Amount (nmol) of free (unbound) Metabolite2 in tumor extracellular space

$$\begin{aligned}
 \frac{d(Meta2_f^{ex})}{dt} = & \underbrace{K_{met}^{Drug,ex} \times \frac{Drug_f^{ex}}{\varepsilon^{Drug}}}_{\text{From metabolism}} + \underbrace{\left(Meta2_f^{C1} - \frac{Meta2_f^{ex}}{V^{tumor} \times \varepsilon^{Meta}} \right) \times V^{tumor} \times \left(\frac{2 \times P_{Meta} \times R_{Cap}}{R_{Krogh}^2} + \frac{6 \times D_{Meta}}{R_{Tumor}^2} \right)}_{\text{From central space}} \\
 & + \underbrace{K_{out}^{Meta,ex} \times Meta2_f^{cell,cyto} \times NC^{tumor} \times SF}_{\text{Fromm efflux of drug from the cell}} - \underbrace{K_{in}^{Meta,ex} \times NC^{tumor} \times \left(\frac{V^{cell}}{V^{tumor} \times \varepsilon^{Meta}} \right) \times Meta2_f^{ex}}_{\text{To influx into cells}} \\
 & + \underbrace{\frac{1}{\tau} \times V_{dyi,3,mm3}^{tumor} \times 10^5 \times \left(Meta2_f^{cell,cyto} + Meta2_{b,dt}^{cell,cyto} + Meta2_f^{cell,lyso} \right) \times SF}_{\text{From intracellular content of dying cells}}
 \end{aligned}$$

Units:

$$\begin{aligned}
 \frac{nmol}{l \times h} = & -\frac{l}{h} / kg \times \frac{nmol}{l} - \frac{l}{h} / kg \times \frac{nmol}{l} + \frac{l}{h} / kg \times \frac{nmol}{l} + \frac{1}{h} \times \frac{nmol}{kg} \times 1 + \frac{l}{h} / kg \times 1 \times \frac{nmol/kg}{l/kg} \\
 & - \left(\frac{nmol}{l} - \frac{nmol}{l \times 1} \right) \times \frac{l}{l/kg \times kg} \times \left(\frac{um}{h} \times um + \frac{cm^2/h}{cm^2} \right) \frac{1}{h} \times \frac{nmol}{l} + \frac{1}{h} \times 1 \times \frac{nmol}{l} + \frac{1}{h} \times 1 \times \frac{1 \times nmol}{kg \times \frac{l}{kg}} - \frac{1}{h} \times \frac{l \times 1}{kg \times \frac{l}{kg}} \times \frac{nmol}{l}
 \end{aligned}$$

Number of free ADC (bound to 0 Protacs) molecules bound to binding target on a single cell

$$\frac{d(ADC_{f,b,ag}^{cell})}{dt} = K_{on}^{ADC,cell,ag} \times \frac{ADC_f^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{\max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{\max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq \max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 A \right)$$

From binding to receptor

$$\begin{aligned} & \underbrace{-K_{off}^{ADC,cell,ag} \times ADC_{f,b,ag}^{cell}}_{\text{To unbinding from receptor}} - \underbrace{K_{int}^{ADC,cell} \times ADC_{f,b,ag}^{cell}}_{\text{To internalization into cell}} - \underbrace{\frac{\ln(2)}{DT_{tumor}} \times ADC_{f,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}} - \underbrace{K_{on}^{Ab,Drug} \times 2 \times ADC_{f,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{To binding to drug}} \\ & \underbrace{+K_{off}^{Ab,Drug} \times ADC_{b1,b,ag}^{cell}}_{\text{From unbinding of drug}} - \underbrace{K_{on}^{Ab,Meta} \times 2 \times ADC_{f,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times ADC_{m1,b,ag}^{cell}}_{\text{From unbinding of metabolite}} \end{aligned}$$

Units: $\frac{1}{h} = \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol/l}{1} \times (1 - 1 - 1) - \frac{1}{h} \times 1 - \frac{1}{h} \times 1 - \frac{1}{h} \times 1 - \frac{1}{h} \times 1$

Number of ADC molecules bound to 1 Protac bound to binding target on a single cell

$$\frac{d(ADC_{b1,b,ag}^{cell})}{dt} = K_{on}^{ADC,cell,ag} \times \frac{ADC_{b1}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{\max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{\max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq \max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 \right)$$

From binding to receptor

$$\underbrace{-K_{off}^{ADC,cell,ag} \times ADC_{b1,b,ag}^{cell}}_{\text{To unbinding from receptor}} - \underbrace{K_{int}^{ADC,cell} \times ADC_{b1,b,ag}^{cell}}_{\text{To internalization into cell}} - \underbrace{\frac{\ln(2)}{DT_{tumor}} \times ADC_{b1,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}} - \underbrace{K_{on}^{Ab,Drug} \times ADC_{b1,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{To binding to drug}}$$

$$\underbrace{+K_{off}^{Ab,Drug} \times ADC_{b2,b,ag}^{cell}}_{\text{From unbinding of drug}} + \underbrace{+K_{on}^{Ab,Drug} \times 2 \times ADC_{f,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times ADC_{b1,b,ag}^{cell}}_{\text{To unbinding of drug}}$$

$$\underbrace{-K_{on}^{Ab,Meta} \times ADC_{b1,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{To binding to metabolite}} + \underbrace{+K_{off}^{Ab,Meta} \times ADC_{b1,m1,b,ag}^{cell}}_{\text{From unbinding of metabolite}}$$

To binding to metabolite

From unbinding of metabolite

Number of ADC molecules bound to 2 Protacs bound to binding target on a single cell

$$\frac{d(ADC_{b2,b,ag}^{cell})}{dt} = K_{on}^{ADC,cell,ag} \times \frac{ADC_{b2}^{ex}}{\varepsilon^{ADC}} \times \underbrace{\left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 \right)}_{\text{From binding to receptor}}$$

$$\underbrace{-K_{off}^{ADC,cell,ag} \times ADC_{b2,b,ag}^{cell}}_{\text{To unbinding from receptor}} \underbrace{-K_{int}^{ADC,cell} \times ADC_{b2,b,ag}^{cell}}_{\text{To internalization into cell}} \underbrace{-\frac{\ln(2)}{DT^{tumor}} \times ADC_{b2,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}}$$

$$\underbrace{+K_{on}^{Ab,Drug} \times ADC_{b1,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V^{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} \underbrace{-K_{off}^{Ab,Drug} \times ADC_{b2,b,ag}^{cell}}_{\text{To unbinding of drug}}$$

Units: $\frac{1}{h} = \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol/l}{1} \times (1 - 1 - 1) - \frac{1}{h} \times 1 - \frac{1}{h} \times 1 - \frac{1}{h} \times 1 - \frac{1}{h} \times 1$

Number of ADC molecules bound to 1 Metabolite1 bound to binding target on a single cell

$$\begin{aligned}
 \frac{d(ADC_{m1,b,ag}^{cell})}{dt} = & \underbrace{K_{on}^{ADC,cell,ag} \times \frac{ADC_{m1}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} \right)}_{\text{From binding to receptor}} \\
 & \underbrace{-K_{off}^{ADC,cell,ag} \times ADC_{m1,b,ag}^{cell}}_{\text{To unbinding from receptor}} \underbrace{-K_{int}^{ADC,cell} \times ADC_{m1,b,ag}^{cell}}_{\text{To internalization into cell}} \underbrace{-\frac{\ln(2)}{DT_{tumor}} \times ADC_{m1,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}} \underbrace{-K_{on}^{Ab,Drug} \times ADC_{m1,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} \\
 & \underbrace{+K_{off}^{Ab,Drug} \times ADC_{b1,m1,b,ag}^{cell}}_{\text{To unbinding of drug}} \underbrace{+K_{on}^{Ab,Meta} \times 2 \times ADC_{f,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{From binding to metabolite}} \\
 & \underbrace{-K_{off}^{Ab,Meta} \times ADC_{m1,b,ag}^{cell}}_{\text{To unbinding of metabolite}} \underbrace{-K_{on}^{Ab,Meta} \times ADC_{m1,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}} + K_{off}^{Ab,Meta} \times ADC_{m2,b,ag}^{cell}}_{\text{To binding to metabolite} \quad \text{From unbinding of metabolite}}
 \end{aligned}$$

Number of ADC molecules bound to 2 Metabolites1 bound to binding target on a single cell

$$\begin{aligned}
 \frac{d(ADC_{m2,b,ag}^{cell})}{dt} = & \underbrace{K_{on}^{ADC,cell,ag} \times \frac{ADC_{m2}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} \right)}_{\text{From binding to receptor}} \\
 & \underbrace{-K_{off}^{ADC,cell,ag} \times ADC_{m2,b,ag}^{cell}}_{\text{To unbinding from receptor}} \underbrace{-K_{int}^{ADC,cell} \times ADC_{m2,b,ag}^{cell}}_{\text{To internalization into cell}} \underbrace{-\frac{\ln(2)}{DT_{tumor}} \times ADC_{m2,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}} \\
 & \underbrace{+K_{on}^{Ab,Meta} \times ADC_{m1,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{From binding to metabolite}} \underbrace{-K_{off}^{Ab,Meta} \times ADC_{m2,b,ag}^{cell}}_{\text{To unbinding of metabolite}}
 \end{aligned}$$

Number of ADC molecules bound 1 Protac and 1 Metabolite1 bound to binding target on a single cell

$$\begin{aligned}
 \frac{d(ADC_{b1,m1,b,ag}^{cell})}{dt} = & \underbrace{K_{on}^{ADC,cell,ag} \times \frac{ADC_{b1,m1}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} \right)}_{\text{From binding to receptor}} \\
 & \underbrace{-K_{off}^{ADC,cell,ag} \times ADC_{b1,m1,b,ag}^{cell}}_{\text{To unbinding from receptor}} \underbrace{-K_{int}^{ADC,cell} \times ADC_{b1,m1,b,ag}^{cell}}_{\text{To internalization into cell}} \underbrace{-\frac{\ln(2)}{DT_{tumor}} \times ADC_{b1,m1,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}} \\
 & \underbrace{+K_{on}^{Ab,Drug} \times ADC_{m1,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} \underbrace{-K_{off}^{Ab,Drug} \times ADC_{b1,m1,b,ag}^{cell}}_{\text{To unbinding of drug}} \\
 & \underbrace{+K_{on}^{Ab,Meta} \times ADC_{b1,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{From binding to metabolite}} \underbrace{-K_{off}^{Ab,Meta} \times ADC_{b1,m1,b,ag}^{cell}}_{\text{To unbinding of metabolite}}
 \end{aligned}$$

Number of free Antibody (bound to 0 Protacs) molecules bound to binding target on a single cell

$$\begin{aligned} \frac{d(Ab_{f,b,ag}^{cell})}{dt} = & K_{on}^{ADC,cell,ag} \times \frac{Ab_f^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \underbrace{\sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell}}_{\text{From binding to receptor}} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{mj,b,ag}^{cell} \right) \\ & - \underbrace{K_{off}^{ADC,cell,ag} \times Ab_{f,b,ag}^{cell}}_{\text{To unbinding from receptor}} - \underbrace{K_{int}^{ADC,cell} \times Ab_{f,b,ag}^{cell}}_{\text{To internalization into cell}} - \underbrace{\frac{\ln(2)}{DT_{tumor}} \times Ab_{f,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}} - \underbrace{K_{on}^{Ab,Drug} \times max \times Ab_{f,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{To binding to drug}} \\ & + \underbrace{K_{off}^{Ab,Drug} \times Ab_{b1,b,ag}^{cell}}_{\text{From unbinding of drug}} - \underbrace{K_{on}^{Ab,Meta} \times max \times Ab_{f,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times Ab_{m1,b,ag}^{cell}}_{\text{From unbinding of metabolite}} \end{aligned}$$

Units: $\frac{1}{h} = \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol/l}{1} \times (1 - 1 - 1) - \frac{1}{h} \times 1 - \frac{1}{h} \times 1 - \frac{1}{h} \times 1 - \frac{1}{h} \times 1$

Number of Antibody molecules bound to i Protacs bound to binding target on a single cell, i = 1,2,3

$$\frac{d(Ab_{bi,b,ag}^{cell})}{dt} = K_{on}^{ADC,cell,ag} \times \frac{Ab_{bi}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 ADC_{bi,b,ag}^{cell} \right)$$

From binding to receptor

$$\underbrace{-K_{off}^{ADC,cell,ag} \times Ab_{bi,b,ag}^{cell}}_{\text{To unbinding from receptor}} - \underbrace{K_{int}^{ADC,cell} \times Ab_{bi,b,ag}^{cell}}_{\text{To internalization into cell}} - \underbrace{\frac{\ln(2)}{DT_{tumor}} \times Ab_{bi,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}} - \underbrace{K_{on}^{Ab,Drug} \times (max - i) \times Ab_{bi,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{To binding to drug}}$$

$$\underbrace{+K_{off}^{Ab,Drug} \times Ab_{bi+1,b,ag}^{cell}}_{\text{From unbinding of drug}} + \underbrace{+K_{on}^{Ab,Drug} \times (max - i + 1) \times Ab_{bi-1,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi,b,ag}^{cell}}_{\text{To unbinding of drug}}$$

$$\underbrace{-K_{on}^{Ab,Meta} \times (max - i) \times Ab_{bi,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times Ab_{bi,m1,b,ag}^{cell}}_{\text{From unbinding of metabolite}}$$

To binding to metabolite

From unbinding of metabolite

Units: $\frac{1}{h} = \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol/l}{1} \times (1 - 1 - 1) - \frac{1}{h} \times 1 - \frac{1}{h} \times 1 - \frac{1}{h} \times 1 - \frac{1}{h} \times 1$

Number of Antibody molecules bound to 4 Protacs bound to binding target on a single cell

$$\frac{d(Ab_{b4,b,ag}^{cell})}{dt} = K_{on}^{ADC,cell,ag} \times \frac{Ab_{b4}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \underbrace{\sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell}}_{\text{From binding to receptor}} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 AD \right)$$

$$\begin{aligned} & \underbrace{-K_{off}^{ADC,cell,ag} \times Ab_{b4,b,ag}^{cell}}_{\text{To unbinding from receptor}} - \underbrace{K_{int}^{ADC,cell} \times Ab_{b4,b,ag}^{cell}}_{\text{To internalization into cell}} - \underbrace{\frac{\ln(2)}{DT_{tumor}} \times Ab_{b4,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}} \\ & + \underbrace{K_{on}^{Ab,Drug} \times Ab_{b3,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times Ab_{b4,b,ag}^{cell}}_{\text{To unbinding of drug}} \end{aligned}$$

Units: $\frac{1}{h} = \frac{1}{\frac{nmol}{l} \times h} \times \frac{nmol/l}{1} \times (1 - 1 - 1) - \frac{1}{h} \times 1 - \frac{1}{h} \times 1 - \frac{1}{h} \times 1 - \frac{1}{h} \times 1$

Number of Antibody molecules bound to j Metabolites1 bound to binding target on a single cell, j = 1,2,3

$$\begin{aligned}
 \frac{d(Ab_{mj,b,ag}^{cell})}{dt} = & \underbrace{K_{on}^{ADC,cell,ag} \times \frac{Ab_{mj}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 A_{mj,b,ag}^{cell} \right)}_{\text{From binding to receptor}} \\
 & \underbrace{-K_{off}^{ADC,cell,ag} \times Ab_{mj,b,ag}^{cell}}_{\text{To unbinding from receptor}} - \underbrace{K_{int}^{ADC,cell} \times Ab_{mj,b,ag}^{cell}}_{\text{To internalization into cell}} - \underbrace{\frac{\ln(2)}{DT_{tumor}} \times Ab_{mj,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}} - \underbrace{K_{on}^{Ab,Drug} \times (max - j) \times Ab_{mj,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^D}}_{\text{From binding to drug}} \\
 & \underbrace{+K_{off}^{Ab,Drug} \times Ab_{b1,mj,b,ag}^{cell}}_{\text{To unbinding of drug}} + \underbrace{K_{on}^{Ab,Meta} \times (max - j + 1) \times Ab_{mj-1,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{From binding to metabolite}} \\
 & \underbrace{-K_{off}^{Ab,Meta} \times Ab_{mj,b,ag}^{cell}}_{\text{To unbinding of metabolite}} - \underbrace{K_{on}^{Ab,Meta} \times (max - j) \times Ab_{mj,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{To binding to metabolite}} + \underbrace{K_{off}^{Ab,Meta} \times Ab_{mj+1,b,ag}^{cell}}_{\text{From unbinding of metabolite}}
 \end{aligned}$$

Number of Antibody molecules bound to 4 Metabolites1 bound to binding target on a single cell

$$\begin{aligned}
 \frac{d(Ab_{m4,b,ag}^{cell})}{dt} = & \underbrace{K_{on}^{ADC,cell,ag} \times \frac{Ab_{m4}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 Ab_{mj,b,ag}^{cell} \right)}_{\text{From binding to receptor}} \\
 & - \underbrace{K_{off}^{ADC,cell,ag} \times Ab_{m4,b,ag}^{cell}}_{\text{To unbinding from receptor}} - \underbrace{K_{int}^{ADC,cell} \times Ab_{m4,b,ag}^{cell}}_{\text{To internalization into cell}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times Ab_{m4,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}} \\
 & + \underbrace{K_{on}^{Ab,Meta} \times Ab_{m3,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V^{tumor} \times \varepsilon^{Meta}}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times Ab_{m4,b,ag}^{cell}}_{\text{To unbinding of metabolite}}
 \end{aligned}$$

Number of Antibody molecules bound i Protacs and j Metabolites1 bound to binding target on a single cell, i = 1,2 and j = 1,2

$$\begin{aligned}
 \frac{d(Ab_{bi,mj,b,ag}^{cell})}{dt} = & \underbrace{K_{on}^{ADC,cell,ag} \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 \right)}_{\text{From binding to receptor}} \\
 & \underbrace{-K_{off}^{ADC,cell,ag} \times Ab_{bi,mj,b,ag}^{cell}}_{\text{To unbinding from receptor}} - \underbrace{K_{int}^{ADC,cell} \times Ab_{bi,mj,b,ag}^{cell}}_{\text{To internalization into cell}} - \underbrace{\frac{\ln(2)}{DT_{tumor}} \times Ab_{bi,mj,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}} \\
 & \underbrace{-K_{on}^{Ab,Drug} \times (max - i - j) \times Ab_{bi,mj,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{To binding to drug}} + \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi+1,mj,b,ag}^{cell}}_{\text{From unbinding of drug}} - \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi,mj,b,ag}^{cell}}_{\text{To unbinding of drug}} \\
 & \underbrace{+K_{on}^{Ab,Drug} \times (max - i + 1 - j) \times Ab_{bi-1,mj,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} - \underbrace{K_{on}^{Ab,Meta} \times (max - i - j) \times Ab_{bi,mj,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{To binding to metabolite}} \\
 & \underbrace{+K_{off}^{Ab,Meta} \times Ab_{bi,mj+1,b,ag}^{cell}}_{\text{From unbinding of metabolite}} + \underbrace{K_{on}^{Ab,Meta} \times (max - i - j + 1) \times Ab_{bi,mj-1,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times Ab_{bi,mj,b,ag}^{cell}}_{\text{To unbinding of metabolite}}
 \end{aligned}$$

Number of Antibody molecules bound i Protacs and j Metabolites1 bound to binding target on a single cell, i = 1,2,3 and j = 1,2,3 with i + j = max

$$\begin{aligned}
 \frac{d(Ab_{bi,mj,b,ag}^{cell})}{dt} = & \underbrace{K_{on}^{ADC,cell,ag} \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC}} \times \left(Ag_t^{cell} - \sum_{i=0}^{max} Ab_{bi,b,ag}^{cell} - \sum_{j=1}^{max} Ab_{mj,b,ag}^{cell} - \sum_{i,j=1}^{i+j \leq max} Ab_{bi,mj,b,ag}^{cell} - \sum_{i=0}^2 ADC_{bi,b,ag}^{cell} - \sum_{j=1}^2 \right)}_{\text{From binding to receptor}} \\
 & \underbrace{-K_{off}^{ADC,cell,ag} \times Ab_{bi,mj,b,ag}^{cell}}_{\text{To unbinding from receptor}} - \underbrace{K_{int}^{ADC,cell} \times Ab_{bi,mj,b,ag}^{cell}}_{\text{To internalization into cell}} - \underbrace{\frac{\ln(2)}{DT_{tumor}} \times Ab_{bi,mj,b,ag}^{cell}}_{\text{To dilution as cells grow and divide}} \\
 & \underbrace{+K_{on}^{Ab,Drug} \times (max - i + 1 - j) \times Ab_{bi-1,mj,b,ag}^{cell} \times \frac{Drug_f^{ex}}{V_{tumor} \times \varepsilon^{Drug}}}_{\text{From binding to drug}} - \underbrace{K_{off}^{Ab,Drug} \times Ab_{bi,mj,b,ag}^{cell}}_{\text{To unbinding of drug}} \\
 & \underbrace{+K_{on}^{Ab,Meta} \times (max - i - j + 1) \times Ab_{bi,mj-1,b,ag}^{cell} \times \frac{Meta1_f^{ex}}{V_{tumor} \times \varepsilon^{Meta}}}_{\text{From binding to metabolite}} - \underbrace{K_{off}^{Ab,Meta} \times Ab_{bi,mj,b,ag}^{cell}}_{\text{To unbinding of metabolite}}
 \end{aligned}$$

Number of ADC molecules bound to i Protacs internalized in endosomal/lysosomal space on a single cell, i = 1,2

$$\frac{d(ADC_{bi}^{cell,lyso})}{dt} = \underbrace{K_{int}^{ADC,cell} \times ADC_{bi,b,ag}^{cell}}_{\text{From internalization into cell}}$$

$$\underbrace{-K_{deg}^{ADC} \times ADC_{bi}^{cell,lyso}}_{\text{To degradation}} + \underbrace{K_{pino}^{ADC,cell,lyso} \times \frac{ADC_{bi}^{ex}}{\epsilon^{ADC} \times SF}}_{\text{From pinocytosis}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times ADC_{bi}^{cell,lyso}}_{\text{To dilution as cells grow and divide}}$$

Units: $\frac{1}{h} = \frac{1}{h} \times 1 - \frac{1}{h} \times 1 + \frac{l}{h} \times \frac{nmol/l}{1 \times nmol} - \frac{1}{h} \times 1$

Number of ADC molecules bound to j Metabolites1 internalized in endosomal/lysosomal space on a single cell, j = 1,2

$$\frac{d(ADC_{mj}^{cell,lyso})}{dt} = \underbrace{K_{int}^{ADC,cell} \times ADC_{mj,b,ag}^{cell}}_{\text{From internalization into cell}}$$

$$\underbrace{-K_{deg}^{ADC} \times ADC_{mj}^{cell,lyso}}_{\text{To degradation}} + \underbrace{K_{pino}^{ADC,cell,lyso} \times \frac{ADC_{mj}^{ex}}{\varepsilon^{ADC} \times SF}}_{\text{From pinocytosis}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times ADC_{mj}^{cell,lyso}}_{\text{To dilution as cells grow and divide}}$$

Units: $\frac{1}{h} = \frac{1}{h} \times 1 - \frac{1}{h} \times 1 + \frac{l}{h} \times \frac{nmol/l}{1 \times nmol} - \frac{1}{h} \times 1$

Number of ADC molecules bound to 1 Protac and 1 Metabolite1 internalized in endosomal/lysosomal space on a single cell

$$\frac{d(ADC_{b1,m1}^{cell,lyso})}{dt} = \underbrace{K_{int}^{ADC,cell} \times ADC_{b1,m1,b,ag}^{cell}}_{\text{From internalization into cell}}$$

$$\underbrace{-K_{deg}^{ADC} \times ADC_{b1,m1}^{cell,lyso}}_{\text{To degradation}} + \underbrace{K_{pino}^{ADC,cell,lyso} \times \frac{ADC_{b1,m1}^{ex}}{\varepsilon^{ADC} \times SF}}_{\text{From pinocytosis}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times ADC_{b1,m1}^{cell,lyso}}_{\text{To dilution as cells grow and divide}}$$

Units: $\frac{1}{h} = \frac{1}{h} \times 1 - \frac{1}{h} \times 1 + \frac{l}{h} \times \frac{nmol/l}{1 \times nmol} - \frac{1}{h} \times 1$

Number of Antibody molecules bound to i Protacs internalized in endosomal/lysosomal space on a single cell, $i = 1,2,3,4$

$$\frac{d(Ab_{bi}^{cell,lyso})}{dt} = \underbrace{K_{int}^{ADC,cell} \times Ab_{bi,b,ag}^{cell}}_{\text{From internalization into cell}}$$

$$\underbrace{-K_{deg}^{ADC} \times Ab_{bi}^{cell,lyso}}_{\text{To degradation}} + \underbrace{K_{pino}^{ADC,cell,lyso} \times \frac{Ab_{bi}^{ex}}{\epsilon^{ADC} \times SF}}_{\text{From pinocytosis}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times Ab_{bi}^{cell,lyso}}_{\text{To dilution as cells grow and divide}}$$

Units: $\frac{1}{h} = \frac{1}{h} \times 1 - \frac{1}{h} \times 1 + \frac{l}{h} \times \frac{nmol/l}{1 \times nmol} - \frac{1}{h} \times 1$

Number of Antibody molecules bound to j Metabolites1 internalized in endosomal/lysosomal space on a single cell, j = 1,2,3,4

$$\frac{d(Ab_{mj}^{cell,lyso})}{dt} = \underbrace{K_{int}^{ADC,cell} \times Ab_{mj,b,ag}^{cell}}_{\text{From internalization into cell}}$$

$$\underbrace{-K_{deg}^{ADC} \times Ab_{mj}^{cell,lyso}}_{\text{To degradation}} + \underbrace{K_{pino}^{ADC,cell,lyso} \times \frac{Ab_{mj}^{ex}}{\varepsilon^{ADC} \times SF}}_{\text{From pinocytosis}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times Ab_{mj}^{cell,lyso}}_{\text{To dilution as cells grow and divide}}$$

Units: $\frac{1}{h} = \frac{1}{h} \times 1 - \frac{1}{h} \times 1 + \frac{l}{h} \times \frac{nmol/l}{1 \times nmol} - \frac{1}{h} \times 1$

Number of Antibody molecules bound to i Protacs and j Metabolites¹ internalized in endosomal/lysosomal space on a single cell,
 $i = 1,2,3,4$ and $j = 1,2,3,4$ with $i + j \leq \max$

$$\frac{d(Ab_{bi,mj}^{cell,lyso})}{dt} = \underbrace{K_{int}^{ADC,cell} \times Ab_{bi,mj,b,ag}^{cell}}_{\text{From internalization into cell}}$$

$$\underbrace{-K_{deg}^{ADC} \times Ab_{bi,mj}^{cell,lyso}}_{\text{To degradation}} + \underbrace{K_{pino}^{ADC,cell,lyso} \times \frac{Ab_{bi,mj}^{ex}}{\varepsilon^{ADC} \times SF}}_{\text{From pinocytosis}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times Ab_{bi,mj}^{cell,lyso}}_{\text{To dilution as cells grow and divide}}$$

Units: $\frac{1}{h} = \frac{1}{h} \times 1 - \frac{1}{h} \times 1 + \frac{l}{h} \times \frac{nmol/l}{1 \times nmol} - \frac{1}{h} \times 1$

Number of free (unbound) drug molecules in endosomal/lysosomal space on a single cell

$$\frac{d(Drug_f^{cell,lyso})}{dt} = \underbrace{\sum_{i,j=1}^{\max} K_{deg}^{ADC} \times (Ab_{bi}^{cell,lyso} + Ab_{bi,mj}^{cell,lyso}) \times i}_{\text{From degradation of Shuttle}} - \underbrace{K_{out}^{Drug,lyso} \times \left(\frac{V^{cell}}{V^{cell,lyso}} \right) \times Drug_f^{cell,lyso}}_{\text{To cytosol}}$$

$$+ \underbrace{K_{in}^{Drug,lyso} \times Drug_f^{cell,cyto}}_{\text{From cytosol}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times Drug_f^{cell,lyso}}_{\text{To dilution as cells grow and divide}} - \underbrace{K_{met}^{Drug,cell} \times Drug_f^{cell,lyso}}_{\text{To metabolism}}$$

$$+ \underbrace{K_{deg}^{ADC} \times (ADC_{b1}^{cell,lyso} + ADC_{b2}^{cell,lyso} \times 2 + ADC_{b1,m1}^{cell,lyso})}_{\text{From degradation of non-covalent bound Protac of ADC}} + \underbrace{K_{deg}^{ADC} \times \left(\sum_{i=1}^2 ADC_{bi}^{cell,lyso} + \sum_{j=1}^2 ADC_{mj}^{cell,lyso} + ADC_{b1,m1}^{cell,lyso} \right) \times \overline{DAR}}_{\text{From degradation of ADC}}$$

Number of free (unbound) Metabolite1 molecules in endosomal/lysosomal space on a single cell

$$\frac{d(Meta1_f^{cell,lyso})}{dt} = \underbrace{\sum_{i,j=1}^{max} K_{deg}^{ADC} \times (Ab_{mj}^{cell,lyso} + Ab_{bi,mj}^{cell,lyso}) \times j}_{\text{From degradation of ADC}} - \underbrace{K_{out}^{Meta,lyso} \times \left(\frac{V^{cell}}{V^{cell,lyso}} \right) \times Meta1_f^{cell,lyso}}_{\text{To cytosol}}$$

$$\begin{aligned} & + \underbrace{K_{in}^{Meta,lyso} \times Meta1_f^{cell,cyto}}_{\text{From cytosol}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times Meta1_f^{cell,lyso}}_{\text{To dilution as cells grow and divide}} + \underbrace{K_{met}^{Drug,cell} \times Drug_f^{cell,lyso}}_{\text{From metabolism}} \\ & + \underbrace{K_{deg}^{ADC} \times (ADC_{m1}^{cell,lyso} + ADC_{m2}^{cell,lyso} \times 2 + ADC_{b1,m1}^{cell,lyso})}_{\text{From degradation of non-covalent bound Meta1 of ADC}} \end{aligned}$$

Units:

$$\frac{1}{h} = \frac{1}{h} \times (1 + 1) - \frac{1}{h} \times \left(\frac{l}{l} \right) \times 1 + \frac{1}{h} \times 1 - \frac{1}{h} \times 1$$

Number of free (unbound) Metabolite2 molecules in endosomal/lysosomal space on a single cell

$$\frac{d(Meta2_f^{cell,lyso})}{dt} = \underbrace{-K_{out}^{Meta,lyso} \times \left(\frac{V^{cell}}{V^{cell,lyso}} \right) \times Meta2_f^{cell,lyso}}_{\text{To cytosol}}$$

$$\underbrace{+K_{in}^{Meta,lyso} \times Meta2_f^{cell,cyto}}_{\text{From cytosol}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times Meta2_f^{cell,lyso}}_{\text{To dilution as cells grow and divide}} + \underbrace{K_{met}^{Drug,cell} \times Drug_f^{cell,lyso}}_{\text{From metabolism}}$$

Units:

$$\frac{1}{h} = \frac{1}{h} \times (1 + 1) - \frac{1}{h} \times \left(\frac{l}{l} \right) \times 1 + \frac{1}{h} \times 1 - \frac{1}{h} \times 1$$

Number of free (unbound) drug molecules in cytosol on a single cell

$$\begin{aligned}
 \frac{d(\text{Drug}_f^{\text{cell, cyto}})}{dt} = & \underbrace{+K_{\text{out}}^{\text{Drug, lyso}} \times \left(\frac{V^{\text{cell}}}{V^{\text{cell, lyso}}} \right) \times \text{Drug}_f^{\text{cell, lyso}} - K_{\text{in}}^{\text{Drug, lyso}} \times \text{Drug}_f^{\text{cell, cyto}}}_{\text{From and to lysosome}} - \underbrace{K_{\text{out}}^{\text{Drug, ex}} \times \text{Drug}_f^{\text{cell, cyto}}}_{\text{To efflux}} \\
 & - \underbrace{K_{\text{met}}^{\text{Drug, cell}} \times \text{Drug}_f^{\text{cell, cyto}}}_{\text{To metabolism}} + \underbrace{K_{\text{in}}^{\text{Drug, ex}} \times \left(\frac{V^{\text{cell}}}{V^{\text{tumor}} \times \varepsilon^{\text{Drug}}} \right) \times \frac{\text{Drug}_f^{\text{ex}}}{SF}}_{\text{From influx}} - \underbrace{\frac{\ln(2)}{DT^{\text{tumor}}} \times \text{Drug}_f^{\text{cell, cyto}}}_{\text{To dilution as cells grow and divide}} \\
 & - \underbrace{K_{\text{met}}^{\text{Drug}} \times \text{Drug}_f^{\text{cell, cyto}}}_{\text{To metabolism}} + \underbrace{K_{\text{off}}^{\text{Drug, E3}} \times \text{Drug_E3}_b^{\text{cell, cyto}}}_{\text{From unbinding from E3-ligase}} + \underbrace{K_{\text{off}}^{\text{Drug, Target}} \times \text{Drug_DrugTarget}_b^{\text{cell, cyto}}}_{\text{From unbinding from drug target}} \\
 & - \underbrace{\frac{K_{\text{on}}^{\text{Drug, E3}} \times SF}{V^{\text{cell}}} \times \text{Drug}_f^{\text{cell, cyto}} \times \left(\text{E3}_f^{\text{cell, cyto}} - \text{Drug_E3}_b^{\text{cell, cyto}} - \text{Drug}_{b, dt}^{\text{cell, cyto}} - \text{Meta1_E3}_b^{\text{cell, cyto}} \right)}_{\text{To binding to E3-ligase}} \\
 & - \underbrace{\frac{K_{\text{on}}^{\text{Drug, Target}} \times SF}{V^{\text{cell}}} \times \text{Drug}_f^{\text{cell, cyto}} \times \left(\text{DrugTarget}_f^{\text{cell, cyto}} - \text{Drug_DrugTarget}_b^{\text{cell, cyto}} - \text{Drug}_{b, dt}^{\text{cell, cyto}} - \text{Meta2_DrugTarget}_b^{\text{cell, cyto}} \right)}_{\text{To binding to drug target}}
 \end{aligned}$$

Number of free (unbound) Metabolite1 molecules in cytosol on a single cell

$$\frac{d(Meta1_f^{cell, cyto})}{dt} = \underbrace{+K_{out}^{Meta, lyso} \times \left(\frac{V^{cell}}{V^{cell, lyso}} \right) \times Meta1_f^{cell, lyso} - K_{in}^{Meta, lyso} \times Meta1_f^{cell, cyto}}_{\text{From and to lysosome}}$$

From and to lysosome

$$\underbrace{-K_{out}^{Meta, ex} \times Meta1_f^{cell, cyto}}_{\text{To efflux}} + \underbrace{K_{in}^{Meta, ex} \times \left(\frac{V^{cell}}{V^{tumor} \times \varepsilon^{Meta}} \right) \times \frac{Meta1_f^{ex}}{SF}}_{\text{From influx}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times Meta1_f^{cell, cyto}}_{\text{To dilution as cells grow and divide}}$$

To efflux

From influx

To dilution as cells grow and divide

$$\underbrace{+K_{met}^{Drug, cell} \times Drug_f^{cell, cyto}}_{\text{From metabolism}} + \underbrace{K_{off}^{Meta, E3} \times Meta1_E3_b^{cell, cyto}}_{\text{From unbinding from E3-ligase}}$$

From metabolism

From unbinding from E3-ligase

$$- \underbrace{\frac{K_{on}^{Meta, E3} \times SF}{V^{cell}} \times Meta1_f^{cell, cyto} \times (E3_f^{cell, cyto} - Drug_E3_b^{cell, cyto} - Drug_{b, dt}^{cell, cyto} - Meta1_E3_b^{cell, cyto})}_{\text{To binding to E3-ligase}}$$

To binding to E3-ligase

Number of free (unbound) Metabolite2 molecules in cytosol on a single cell

$$\begin{aligned}
 \frac{d(Meta2_f^{cell, cyto})}{dt} = & \underbrace{+K_{out}^{Meta, lyso} \times \left(\frac{V^{cell}}{V^{cell, lyso}} \right) \times Meta2_f^{cell, lyso} - K_{in}^{Meta, lyso} \times Meta2_f^{cell, cyto}}_{\text{From and to lysosome}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times Meta2_f^{cell, cyto}}_{\text{To dilution as cells grow and divide}} \\
 & + \underbrace{K_{met}^{Drug, cell} \times Drug_f^{cell, cyto}}_{\text{From metabolism}} - \underbrace{K_{out}^{Meta, ex} \times Meta2_f^{cell, cyto}}_{\text{To efflux}} + \underbrace{K_{in}^{Meta, ex} \times \left(\frac{V^{cell}}{V^{tumor} \times \epsilon^{Meta}} \right) \times \frac{Meta2_f^{ex}}{SF}}_{\text{From influx}} \\
 & - \underbrace{\frac{K_{on}^{Meta, Target} \times SF}{V^{cell}} \times Meta2_f^{cell, cyto} \times \left(DrugTarget_f^{cell, cyto} - Drug_DrugTarget_b^{cell, cyto} - Drug_{b, dt}^{cell, cyto} - Meta2_DrugTarget_b^{cell, cyto} \right)}_{\text{To binding to drug target}} \\
 & + \underbrace{K_{off}^{Meta, Target} \times Meta2_DrugTarget_b^{cell, cyto}}_{\text{From unbinding from drug target}}
 \end{aligned}$$

Number of target and E3-ligase-bound drug molecules in cytosol on a single cell

$$\begin{aligned}
 \frac{d(\text{Drug}_{b,dt}^{\text{cell, cyto}})}{dt} = & \underbrace{-\frac{\ln(2)}{DT_{\text{tumor}}} \times \text{Drug}_{b,dt}^{\text{cell, cyto}}}_{\text{To dilution as cells grow and divide}} \underbrace{- K_{\text{off}}^{\text{Drug, E3}} \times \text{Drug}_{b,dt}^{\text{cell, cyto}}}_{\text{To unbinding from E3-ligase}} \\
 & + \underbrace{\alpha \times \frac{K_{\text{on}}^{\text{Drug, E3}} \times SF}{V^{\text{cell}}} \times \text{Drug_DrugTarget}_b^{\text{cell, cyto}} \times \left(E3_f^{\text{cell, cyto}} - \text{Drug_E3}_b^{\text{cell, cyto}} - \text{Drug}_{b,dt}^{\text{cell, cyto}} - \text{Meta1_E3}_b^{\text{cell, cyto}} \right)}_{\text{From binding to E3-ligase}} \\
 & + \underbrace{\alpha \times \frac{K_{\text{on}}^{\text{Drug, Target}} \times SF}{V^{\text{cell}}} \times \text{Drug_E3}_b^{\text{cell, cyto}} \times \left(\text{DrugTarget}_f^{\text{cell, cyto}} - \text{Drug_DrugTarget}_b^{\text{cell, cyto}} - \text{Drug}_{b,dt}^{\text{cell, cyto}} - \text{Meta2_DrugTarget}_b^{\text{cell, cyto}} \right)}_{\text{From binding to drug target}} \\
 & - \underbrace{K_{\text{off}}^{\text{Drug, Target}} \times \text{Drug}_{b,dt}^{\text{cell, cyto}}}_{\text{To unbinding from drug target}}
 \end{aligned}$$

Number of target molecules in cytosol on a single cell

$$\begin{aligned}
 \frac{d(\text{DrugTarget}_f^{\text{cell, cyto}})}{dt} = & \underbrace{-\frac{\ln(2)}{DT_{\text{tumor}}} \times \text{DrugTarget}_f^{\text{cell, cyto}}}_{\text{To dilution as cells grow and divide}} + \underbrace{K_{\text{off}}^{\text{Drug, Target}} \times \text{Drug_DrugTarget}_b^{\text{cell, cyto}}}_{\text{From unbinding from drug}} \\
 & - \underbrace{\frac{K_{\text{on}}^{\text{Drug, Target}} \times SF}{V_{\text{cell}}} \times \text{Drug}_f^{\text{cell, cyto}} \times \left(\text{DrugTarget}_f^{\text{cell, cyto}} - \text{Drug_DrugTarget}_b^{\text{cell, cyto}} - \text{Drug}_{b, dt}^{\text{cell, cyto}} - \text{Meta2_DrugTarget}_b^{\text{cell, cyto}} \right)}_{\text{To binding to Drug_DrugTarget}_b^{\text{cell, cyto}} \text{ with drug}} \\
 & - \underbrace{\alpha \times \frac{K_{\text{on}}^{\text{Drug, Target}} \times SF}{V_{\text{cell}}} \times \text{Drug_E3}_b^{\text{cell, cyto}} \times \left(\text{DrugTarget}_f^{\text{cell, cyto}} - \text{Drug_DrugTarget}_b^{\text{cell, cyto}} - \text{Drug}_{b, dt}^{\text{cell, cyto}} - \text{Meta2_DrugTarget}_b^{\text{cell, cyto}} \right)}_{\text{To binding to Drug}_{b, dt}^{\text{cell, cyto}} \text{ with Drug_E3}_b^{\text{cell, cyto}}} \\
 & + \underbrace{K_{\text{off}}^{\text{Drug, Target}} \times \text{Drug}_{b, dt}^{\text{cell, cyto}}}_{\text{From unbinding from Drug}_{b, dt}^{\text{cell, cyto}}} - \underbrace{K_{\text{met}}^{\text{Drug}} \times \text{DrugTarget}_f^{\text{cell, cyto}}}_{\text{To metabolism}} + \underbrace{K_{\text{off}}^{\text{Meta, Target}} \times \text{Meta2_DrugTarget}_b^{\text{cell, cyto}}}_{\text{From unbinding from Meta2_DrugTarget}_b^{\text{cell, cyto}}} \\
 & - \underbrace{\frac{K_{\text{on}}^{\text{Meta, Target}} \times SF}{V_{\text{cell}}} \times \text{Meta2}_f^{\text{cell, cyto}} \times \left(\text{DrugTarget}_f^{\text{cell, cyto}} - \text{Drug_DrugTarget}_b^{\text{cell, cyto}} - \text{Drug}_{b, dt}^{\text{cell, cyto}} - \text{Meta2_DrugTarget}_b^{\text{cell, cyto}} \right)}_{\text{To binding to Meta2_DrugTarget}_b^{\text{cell, cyto}} \text{ with Meta2}_f^{\text{cell, cyto}}} + k_{\text{prod}}
 \end{aligned}$$

Number of E3-ligase molecules in cytosol on a single cell

$$\frac{d(E3_f^{cell, cyto})}{dt} = 0$$

Als Konstante!

$$-\frac{k_{on}^{Drug, E3} \times SF}{V_{cell}} \times Drug_f^{cell, cyto} \times E3_f^{cell, cyto}$$

$$+k_{off}^{Drug, E3} \times Drug_E3_b^{cell, cyto} - \frac{k_{on}^{Drug, E3} \times SF}{V_{cell}} \times Drug_DrugTarget_b^{cell, cyto} \times E3_f^{cell, cyto}$$

$$+k_{off}^{Drug, E3} \times Drug_{b, dt}^{cell, cyto} - \frac{\ln(2)}{DT_{tumor}} \times E3_f^{cell, cyto} + k_{prod} \times (E3_f^{cell, cyto}(0) - E3_f^{cell, cyto})$$

Number of E3-ligase-bound drug molecules in cytosol on a single cell

$$\frac{d(\text{Drug_E3}_b^{\text{cell, cyto}})}{dt} = \underbrace{-\frac{\ln(2)}{DT^{\text{tumor}}} \times \text{Drug_E3}_b^{\text{cell, cyto}}}_{\text{To dilution as cells grow and divide}} + \underbrace{K_{\text{off}}^{\text{Drug, Target}} \times \text{Drug}_{b, dt}^{\text{cell, cyto}}}_{\text{From unbinding from drug target}}$$

$$- \underbrace{\alpha \times \frac{K_{\text{on}}^{\text{Drug, Target}} \times SF}{V_{\text{cell}}} \times \text{Drug_E3}_b^{\text{cell, cyto}} \times \left(\text{DrugTarget}_f^{\text{cell, cyto}} - \text{Drug_DrugTarget}_b^{\text{cell, cyto}} - \text{Drug}_{b, dt}^{\text{cell, cyto}} - \text{Meta2_DrugTarget}_b^{\text{cell, cyto}} \right)}_{\text{To binding to drug target}}$$

$$+ \underbrace{\frac{K_{\text{on}}^{\text{Drug, E3}} \times SF}{V_{\text{cell}}} \times \text{Drug}_f^{\text{cell, cyto}} \times \left(\text{E3}_f^{\text{cell, cyto}} - \text{Drug_E3}_b^{\text{cell, cyto}} - \text{Drug}_{b, dt}^{\text{cell, cyto}} - \text{Meta1_E3}_b^{\text{cell, cyto}} \right)}_{\text{From binding to E3-ligase}}$$

$$- \underbrace{K_{\text{off}}^{\text{Drug, E3}} \times \text{Drug_E3}_b^{\text{cell, cyto}}}_{\text{To unbinding from E3-ligase}}$$

Number of target-bound drug molecules in cytosol on a single cell

$$\frac{d(\text{Drug_DrugTarget}_b^{\text{cell, cyto}})}{dt} = \underbrace{-\frac{\ln(2)}{DT_{\text{tumor}}} \times \text{Drug_DrugTarget}_b^{\text{cell, cyto}}}_{\text{To dilution as cells grow and divide}} + \underbrace{K_{\text{off}}^{\text{Drug, E3}} \times \text{Drug}_{b, dt}^{\text{cell, cyto}}}_{\text{From unbinding from E3-ligase}}$$

$$\underbrace{-\alpha \times \frac{K_{\text{on}}^{\text{Drug, E3}} \times SF}{V_{\text{cell}}} \times \left(E3_f^{\text{cell, cyto}} - \text{Drug_E3}_b^{\text{cell, cyto}} - \text{Drug}_{b, dt}^{\text{cell, cyto}} - \text{Meta1_E3}_b^{\text{cell, cyto}} \right) \times \text{Drug_DrugTarget}_b^{\text{cell, cyto}}}_{\text{To binding to E3-ligase}}$$

$$\underbrace{+ \frac{K_{\text{on}}^{\text{Drug, Target}} \times SF}{V_{\text{cell}}} \times \text{Drug}_f^{\text{cell, cyto}} \times \left(\text{DrugTarget}_f^{\text{cell, cyto}} - \text{Drug_DrugTarget}_b^{\text{cell, cyto}} - \text{Drug}_{b, dt}^{\text{cell, cyto}} - \text{Meta2_DrugTarget}_b^{\text{cell, cyto}} \right)}_{\text{From binding to drug target}}$$

$$\underbrace{- K_{\text{off}}^{\text{Drug, Target}} \times \text{Drug_DrugTarget}_b^{\text{cell, cyto}}}_{\text{To unbinding from drug target}}$$

Number of target-bound Metabolite2 molecules in cytosol on a single cell

$$\begin{aligned}
 \frac{d(\text{Meta2_DrugTarget}_b^{\text{cell, cyto}})}{dt} = & \underbrace{-K_{\text{off}}^{\text{Meta, Target}} \times \text{Meta2_DrugTarget}_b^{\text{cell, cyto}}}_{\text{To unbinding from drug target}} - \underbrace{\frac{\ln(2)}{DT_{\text{tumor}}} \times \text{Meta2_DrugTarget}_b^{\text{cell, cyto}}}_{\text{To dilution as cells grow and divide}} \\
 & + \underbrace{\frac{K_{\text{on}}^{\text{Meta, Target}} \times SF}{V_{\text{cell}}} \times \text{Meta2}_f^{\text{cell, cyto}} \times \left(\text{DrugTarget}_f^{\text{cell, cyto}} - \text{Drug_DrugTarget}_b^{\text{cell, cyto}} - \text{Drug}_{b, dt}^{\text{cell, cyto}} \right.}_{\text{From binding to drug target}} \\
 & \quad \left. - \text{Meta2_DrugTarget}_b^{\text{cell, cyto}} \right)
 \end{aligned}$$

Number of E3-ligase-bound Metabolite1 molecules in cytosol on a single cell

$$\frac{d(Meta1_E3_b^{cell, cyto})}{dt} = \underbrace{-K_{off}^{Meta, E3} \times Meta1_E3_b^{cell, cyto}}_{\text{To unbinding from E3-ligase}} - \underbrace{\frac{\ln(2)}{DT^{tumor}} \times Meta1_E3_b^{cell, cyto}}_{\text{To dilution as cells grow and divide}}$$

$$+ \underbrace{\frac{K_{on}^{Meta, E3} \times SF}{V_{cell}} \times Meta1_f^{cell, cyto} \times (E3_f^{cell, cyto} - Drug_E3_b^{cell, cyto} - Drug_{b, dt}^{cell, cyto} - Meta1_E3_b^{cell, cyto})}_{\text{From binding to E3-ligase}}$$

Tumor volume

$$V_{mm3}^{tumor} = V_{pro,mm3}^{tumor} + V_{dyi,1,mm3}^{tumor} + V_{dyi,2,mm3}^{tumor} + V_{dyi,3,mm3}^{tumor}$$

$$\frac{d(V_{pro,mm3}^{tumor})}{dt} = \left(\frac{\frac{\ln(2)}{DT^{tumor}} \times \left(1 - \frac{V_{pro,mm3}^{tumor}}{V_{max}^{tumor}}\right)}{\left(1 + \left(\frac{\ln(2)}{DT^{tumor}} \times \frac{V_{pro,mm3}^{tumor}}{k_{lin}}\right)^\psi\right)^{\frac{1}{\psi}}} - R_{Kill} \right) \cdot V_{pro,mm3}^{tumor}$$

$$\frac{d(V_{dyi,1,mm3}^{tumor})}{dt} = R_{Kill} \cdot V_{pro,mm3}^{tumor} - \frac{1}{\tau} \cdot V_{dyi,1,mm3}^{tumor}$$

$$\frac{d(V_{dyi,2,mm3}^{tumor})}{dt} = \frac{1}{\tau} \cdot (V_{dyi,1,mm3}^{tumor} - V_{dyi,2,mm3}^{tumor})$$

$$\frac{d(V_{dyi,3,mm3}^{tumor})}{dt} = \frac{1}{\tau} \cdot (V_{dyi,2,mm3}^{tumor} - V_{dyi,3,mm3}^{tumor})$$

Logistic (Thomas Rysiok)

$$t_l^{DC} = \ln \left(\frac{Drug_{b,dt}^{cell,cyto} \times SF}{V_{cell}} \right) - \ln(DC_{50})$$

$$LOGI^{DC} = \frac{k_g}{1 + \left(\frac{k_g}{k_z} - 1\right) \times e^{-k_r \times k_g \times t_l^{DC}}}$$

$$t_l^{EC} = \ln \left(\frac{Drug_{b,dt}^{cell,cyto} \times SF}{V_{cell}} \right) - \ln(EC_{50})$$

$$LOGI^{EC} = \frac{k_g}{1 + \left(\frac{k_g}{k_z} - 1\right) \times e^{-k_r \times k_g \times t_l^{EC}}}$$

$$R_{kill} = k_{kill,max} \times \left(\frac{\ln(2)}{DT^{tumor}} \right)^{f_{DT_kill}} \times LOGI^{EC}$$